Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(RULE 14A-101)

INFORMATION REQUIRED IN

PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.     )

Table of Contents

uniQure N.V.

Paasheuvelweg 25a

1105BP1105 BP Amsterdam

The Netherlands

+1-339-970-7000

April 30, 2018May 21, 2020

Dear Shareholder:

On behalf of the Board of Directors of uniQure N.V. (the “Company”), I invite you to attend our 20182020 Annual General Meeting of Shareholders  on June 17, 2020, at 2:30 p.m., Central European Summer Time (the “2018“2020 Annual Meeting”).  The 20182020 Annual Meeting will be held on June 13, 2018,over the Internet via live audio webcast at 9:30 a.m., Central European Summer Timehttp://www.uniqure.com/investors-newsroom/overview.php or, for those who wish to attend in person, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands.

The matters to be voted upon at the 20182020 Annual Meeting are listed in the Notice of the 2018 Annual General Meeting of Shareholders and are more fully described in the proxy statement accompanying this letter (the “Proxy Statement”).

At the 20182020 Annual Meeting, whether you attend in person or over the Internet via live audio webcast, you will be provided an opportunity to ask questions regarding the matters to be voted upon,items on the agenda and gain an up-to-date perspective on the Company and its activities, and meet the directors of the Company.activities.

We have opted to provide our materials in connection with the 2020 Annual Meeting pursuant to the full set delivery option in connection with the 2018 Annual Meeting.option. Under the full set delivery option, a company delivers all proxy materials to its shareholders. Accordingly, you should have receivedare receiving our proxy materials by mail or, if you previously agreed, by e-mail. These proxy materials include thisthe Notice of Annual General Meeting of Shareholders, the Proxy Statement, the proxy card and the Annual Report on Form 10-K. These materials are available free of charge at http://www.edocumentview.com/QURE and, if you are a registered holder, you may vote at http://www.investorvote.com/QURE. Further instructions for accessing the proxy materials and voting are described in the Notice of the 2018 Annual General Meeting of Shareholders and the Proxy Statement.  Your vote is very important.  Whether or not you plan to attend the meeting,2020 Annual Meeting, whether in person or over the Internet via live audio webcast, please carefully review the enclosed proxy statement and then cast your vote, regardless of the number of shares you hold.  If you are a shareholder of record, you may vote over the Internet, by telephone or by completing, signing, dating and mailing the accompanying proxy card in the return envelope. If mailingyou mail the proxy card within the United States, no additional postage is required. Submitting your vote via the Internet or by telephone or proxy card will not affect your right to vote personally during the 2020 Annual Meeting if you attend in person, provided that, if you decideintend to attend the 20182020 Annual Meeting providedin person or over the Internet via live audio webcast, you have notifiedmust notify the Company of your intention to attend the meeting no later than June 11, 2018.16, 2020.  If your shares are held in street name (held for your account by a broker or other nominee), you will receive instructions from your broker or other nominee explaining how to vote your shares and you will have the option to cast your vote by telephone or over the Internet if your voting instruction form from your broker or other nominee includes instructions and a toll-free telephone number or Internet website to do so.  In any event, to be sure that your vote will be received in time (and no later than 6:00 p.m. Central European Summer Time on June 16, 2020), please cast your vote by your choice of available means at your earliest convenience.

Although our 2020 Annual Meeting is held in person, it may not be possible for many of our shareholders, directors, employees and agents to attend this year’s meeting by traditional means due to the quickly evolving situation with COVID-19 around the globe.  Therefore, we will be providing the ability, for those who would like to attend the meeting but cannot or do not want to do so in person, to attend the meeting via a virtual meeting function. In particular, your attention is drawn to the proxy voting methods set out in the Proxy Statement and the ability to vote by Internet, telephone or mail and to ask questions through the Internet in advance of and during the 2020 Annual Meeting, which ensure that shareholders can participate in the 2020 Annual Meeting remotely instead of attending in person.

Table of Contents

uniQure N.V.

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

June 13, 201817, 2020

To the Shareholders of uniQure N.V.:

Notice is hereby given that the 20182020 Annual General Meeting of Shareholders (the “2018“2020 Annual Meeting”) of uniQure N.V., a public company with limited liability (naamloze vennootschap) under the laws of the Netherlands (the “Company,”, “uniQure,” and “we”), will be held on June 13, 2018,17, 2020, at 9:2:30 a.m.p.m., Central European Summer Time, in-person at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands and over the Internet via live audio webcast for the following purposes:

Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above.

A number of the agenda items are presented to the 20182020 Annual Meeting as a result ofbecause our Company beingis organized under the laws of the Netherlands. Several matters that are within the authority of the Board under the corporate laws of most U.S. states require shareholder approval under Dutch law. Additionally, Dutch corporate governance provisions require certain discussion topics for an annual general meeting of shareholders upon which shareholders do not vote.

The Board has fixed the close of business Eastern Time on May 16, 201820, 2020 as the record date and, therefore, only the Company’s shareholders of record at the close of business Eastern Time on May 16, 201820, 2020 are entitled to receive this notice (this “Notice”) and to vote at the 20182020 Annual Meeting and any adjournment thereof.

Table of Contents

Only shareholders who have given notice in writing to the Company by June 11, 201816, 2020 of their intention to attend the 20182020 Annual Meeting in person or over the Internet via live audio webcast are entitled to so attend the 20182020 Annual Meeting in person.Meeting. The conditions for attendance at the 20182020 Annual Meeting are as follows:

1.                                      Shareholders of record (“Registered Shareholders”) must (i) notify the Company of their intention to attend the 20182020 Annual Meeting in person or over the Internet via live audio webcast by submitting their name and the number of registered shares held by them through the Company’s email address at investors@uniQure.com no later than June 11, 201816, 2020 and (ii) bringfor in-person attendance provide a form of personal picture identification toat the 20182020 Annual Meeting; and

2.                                      Holders of shares held in street name (“Beneficial Holders”) must have their financial intermediary, agent or broker with whom the shares are on deposit issue a proxy to them whichthat confirms they are authorized to take part in and vote at the 20182020 Annual Meeting. These Beneficial Holders must (i) notify the Company of their intention to attend the 20182020 Annual Meeting in person or over the Internet via live audio webcast by submitting their name and the number of shares beneficially owned by them through the Company’s email address at investors@uniQure.com no later than June 11, 2018,16, 2020, (ii) bringfor in-person attendance provide an account statement or a letter from the record holder indicating that youthey owned the shares as of the record date toat the 20182020 Annual Meeting, (iii) bringfor in-person attendance provide the proxy issued to them by their financial intermediary, toagent or broker at the 20182020 Annual Meeting and (iv) bringfor in-person attendance provide a form of personal picture identification toat the 20182020 Annual Meeting.

A proxy statement more fully describing the matters to be considered at the 20182020 Annual Meeting (the “Proxy Statement”) is attached to this Notice.  Copies of our Annual Report on Form 10-K for the year ended December 31, 20172019 (the “Annual Report on Form 10-K”), including our financial statements and notes thereto, as filed with the Securities and Exchange Commission, accompany this Notice, but are not deemed to be part of the Proxy Statement.

We have opted to provide our materials in connection with the 2020 Annual Meeting pursuant to the full set delivery option in connection with the 2018 Annual Meeting.option. Under the full set delivery option, a company delivers all proxy materials to its shareholders. This delivery can be by mail or, if a shareholder has previously agreed, by e-mail. Accordingly, you are receiving our proxy materials by mail or, if you previously agreed, by e-mail. These proxy materials include this Notice, the Proxy Statement, the proxy card and the Annual Report on Form 10-K. In addition to delivering proxy materials to shareholders, a company must also post all proxy materials on a publicly accessible website and provide information to stockholdersshareholders about how to access that website. Accordingly, you should have received our proxy materials by mail or, if you previously agreed, by e-mail. These proxy materials include this Notice of Annual Meeting of Shareholders, Proxy Statement, proxy card and the Annual Report on Form 10-K. These materials are available free of charge at http://www.edocumentview.com/QURE.

Our 20172019 Dutch statutory annual accounts are available on our website at www.uniqure.com.

The 2020 Annual Meeting is an important event in the Company’s corporate calendar and provides an opportunity to engage with shareholders and for shareholders to pass the necessary resolutions for the conduct of the business and affairs of the Company. In light of the evolving coronavirus (COVID-19) pandemic and public health concerns, the Board is closely monitoring how matters develop over the coming weeks. As we are sensitive to the public health and travel concerns our shareholders may have and the protocols that governments have and may impose, we will also be providing the ability, for those who would like to attend the meeting but cannot or do not want to do so in person, to attend the meeting via a virtual meeting function. If public health developments warrant, we may need to change the location or format of the 2020 Annual Meeting. Any such change will be announced as promptly as practicable.

The health and wellbeing of our colleagues, shareholders and the communities in which we operate is a priority for us. However, we are also committed to ensuring that shareholders can exercise their right to vote and ask questions at the upcoming 2020 Annual Meeting. In particular, your attention is drawn to the proxy voting methods set out below and the ability to vote by internet, telephone or mail and to ask questions via the Internet in advance of and during the 2020 Annual Meeting, which ensure that shareholders can participate in the 2020 Annual Meeting remotely instead of attending in person. Any questions asked via the Internet in advance of the 2020 Annual Meeting must be submitted to investors@uniQure.com no later than 6:00 p.m. Central European Summer Time on June 15, 2020. The aim is to answer all questions so submitted during the 2020 Annual Meeting.

Table of Contents

NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in the following proxy statement for the 20182020 Annual General Meeting of Shareholders are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended  or the Exchange Act,(the “Exchange Act”), and are subject to the safe harbor created by those sections. Forward-looking statements are based on our current assumptions, projections and expectations of future events, and are generally identified by words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions, or the negatives thereof, or future dates. Forward-looking statements involveare subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. The most significant factors known to us that could materially adversely affect our business, operations, industry, financial position or future financial performance are described in “Part I, Item 1A, Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission or SEC,(the “SEC”) on March 14, 2018, in “Part I, Item 1A, Risk Factors2, 2020  (the “Annual Report on Form 10-K”),” which is being provided to you together with this proxy statement. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made, and should recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results due to the risks and uncertainties described in our Annual Report on Form 10-K, including in “Part I, Item 1A. Risk Factors,” as well as others that we may consider immaterial or do not anticipate at this time. The risks and uncertainties described in our Annual Report on Form 10-K are not exclusive and further information concerning our company and our businesses,business, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. We undertake no obligation to update forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that we file with or furnish to the SEC.

uniQure N.V.

Paasheuvelweg 25a

1105BP1105 BP Amsterdam

The Netherlands

+1-339-970-7000

PROXY STATEMENT FOR THE 20182020 ANNUAL GENERAL MEETING OF SHAREHOLDERS

To Be Held on June 13, 201817, 2020 at 9:2:30 a.m.p.m., Central European Summer Time

This proxy statement (the “Proxy Statement”), which includes the explanatory notes to the agenda for the 20182020 Annual General Meeting of Shareholders (the “2018“2020 Annual Meeting”), and the accompanying proxy card (the “Proxy Card”), are being furnished with respect to the solicitation of proxies by the Board of Directors (the “Board”) of uniQure N.V., a public company with limited liability (naamloze vennootschap) under the laws of the Netherlands (the “Company,” “uniQure” or “we”), for the 20182020 Annual Meeting.  The 20182020 Annual Meeting will be held at 9:2:30 a.m.p.m. Central European Summer Time, on June 13, 2018,17, 2020, and at any adjournment thereof, in person at the Company’s principal executive offices, Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands.Netherlands, and over the Internet via live audio webcast.

The approximate date on which the Proxy Statement and Proxy Card are intended to be first being sent or given to the Company’s shareholders (each a “Shareholder”,“Shareholder and collectively, the “Shareholders”) is May 16, 2018.20, 2020.

The purposes of the 20182020 Annual Meeting are to discuss andand/or vote on the following:

Who May Vote

Shareholders of record of our ordinary shares (the “Ordinary Shares”) as ofat the close of business Eastern Time on May 16, 201820, 2020 (the “Record Date”) are entitled to receive notice of and to vote at the 20182020 Annual Meeting and any adjournment thereof.  On March 31, 2018,2020, we had issued and outstanding 31,771,81644,299,596 Ordinary Shares.  We have no other securities entitled to vote at the 20182020 Annual Meeting.  Each Ordinary Share is entitled to one vote on each matter. There is no cumulative voting.

A list of Shareholders entitled to vote at the 20182020 Annual Meeting will be available at the 20182020 Annual Meeting and will also be available for ten (10) days prior to the 20182020 Annual Meeting, during regular office hours, at the principal executive offices of the Company, located at Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands, by contacting investor relations.Investor Relations at uniQure N.V., Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands, by telephone at +1-339-970-7000, or by email to investors@uniQure.com.

Each matter proposed by the Board shall be adopted by a simple majority of the votes cast at the 2018 Annual Meeting. Under the Company’s Articles of Association and the Nasdaq rules, the presence at the 20182020 Annual Meeting of 33 1/3% of the outstanding Ordinary Shares, representedissued share capital, present in person or represented by proxy, is required for a quorum. “Abstentions” and “broker non-votes,” if any, will be counted as present and entitled to vote for purposes of determining whether a quorum is present for the transaction of business at the meeting.

Each matter proposed by the Board, other than with respect to the appointment of directors and the exclusion or limitation of preemptive rights upon the issuance of Ordinary Shares and granting of rights to subscribe for Ordinary Shares, shall be adopted by a simple majority of the votes cast at the 2020 Annual Meeting. Brokers will have discretion to vote only with respect to Voting Proposal No. 10.

Consistent with Dutch law and the Company’s Articles of Association, executive directors and non-executive directors are appointed by a general meeting from a binding nomination by the non-executive directors. The proposed candidate specified in the binding nomination shall be appointed, provided that the requisite quorum is present or represented at the general meeting, unless the nomination is overruled by the general meeting (which would result if a majority of at least two-thirds of the votes cast, which majority represents more than half of the issued share capital, vote “against” the appointment of such director, with abstentions, “blank votes”, “broker non-votes” and invalid votes not considered votes cast), in which case he or she will not be appointed.

“Broker non-votes” are shares represented at the 20182020 Annual Meeting held by brokers, bankers or other nominees (i.e., in “street name”) andthat are not voted on a particular proposal because the nominee does not have discretionary voting power with respect to that item and has not received instructions from the beneficial owner. Generally, brokerage firms may vote to ratify the selection of independent auditors and on other “discretionary” or “routine” items. In contrast, brokerage firms may not vote to electappoint directors, because those proposals are considered “non-discretionary” items. Accordingly, if you do not instruct your broker how to vote your shares on “non-discretionary” matters, your broker will not be permitted to vote your shares on these matters.  This is a “broker non- vote.”

Methods of Voting

If you wereare a record holder of Ordinary Shares at the close of business Eastern Time on May 16, 2018,20, 2020, you may vote as follows:

·                  By Internet.  Access the website of the Company’s tabulator, Computershare, at: http://www.investorvote.com/QURE, using the voter control number printed on the furnished proxy card.  Your shares will be voted in accordance with your instructions.  You must specify how you want your shares voted or your Internet vote cannot be completed and you will receive an error message.  If you vote on the Internet, you also may request electronic delivery of future proxy materials.

·                  By Telephone.  Call 1-800-652-8683 toll-free from the U.S., U.S. territories and Canada and follow the instructions on the enclosed proxy card.  Your shares will be voted in accordance with your instructions.  You must specify how you want your shares voted or your telephone vote cannot be completed. You must have the control number that is included on the proxy card when voting.

·                  By Mail.  Complete and mail a proxy card in the enclosed postage prepaid envelope to the address provided.  Your proxyshares will be voted in accordance with your instructions.  If you are mailed or otherwise receive or obtain a proxy card, and you choose to vote by telephone or by Internet, you do not have to return your proxy card.

·                  In Personperson at the Meeting.  If you attend the 20182020 Annual Meeting in person, be sure to bringprovide a form of personal picture identification with you.at the meeting. You may deliver your completed proxy card in person, or you may vote by completing a ballot, which will be available at the meeting.  Directions to the 2020 Annual Meeting are available by contacting Investor Relations at , uniQure N.V., Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands, telephone number +1-339-970-7000, email investors@uniQure.com.

If you attend the 2020 Annual Meeting over the Internet via live audio webcast, you will not be able to vote the shares you hold in real time over the Internet via live audio webcast, so please ensure that you vote in advance of the 2020 Annual Meeting by Internet, by telephone or by mail, such in accordance with the above instructions. To be sure that your vote will be received in time (and no later than 6:00 p.m. Central European Summer Time on June 16, 2020), please cast your vote by your choice of available means at your earliest convenience.

If your Ordinary Shares are held in street name (held for your account by a broker or other nominee) at the close of business Eastern Time on May 16, 2018,20, 2020, you may vote:

·                  By Internet or By Telephone. You will receive instructions from your broker or other nominee if you are permitted to vote by internet or telephone.

·                  By Mail. You will receive instructions from your broker or other nominee explaining how to vote your shares.

·                  In Person at the Meeting. If you attend the meeting,2020 Annual Meeting in person, in addition to a form of personal picture identification, you should bring an account statement or a letter from the record holder indicating that you owned the shares as of the record date, and contact the broker or other nominee who holds your shares to obtain a broker’s proxy card and bringprovide it with you toat the meeting.

If you attend the 2020 Annual Meeting over the Internet via live audio webcast, you will not be able to vote the shares you hold in street name in real time over the Internet via live audio webcast, so please ensure that you vote in advance of the 2020 Annual Meeting by Internet, by telephone or by mail, such in accordance with the above instructions. To be sure that your vote will be received in time (and no later than 6:00 p.m. Central European Summer Time on June 16, 2020), please cast your vote by your choice of available means at your earliest convenience.

Board’s Recommendations

The Board recommends a vote:

·                  Voting Proposal No. 1: “FOR” adoption of the 20172019 Dutch statutory annual accounts and treatment of the results.

·                  Voting Proposal No. 2: “FOR” discharge of liability of the members of the Board.

·                  Voting Proposal No. 3: “FOR” reelectionreappointment of Philip Astley-SparkeMadhavan Balachandran as a non-executive director.

·                  Voting Proposal No. 4: “FOR” electionreappointment of Robert GutJack Kaye as a non-executive director.

·                  Voting Proposal No. 5: “FOR” the amendment to the 2014 Restated Plan.reappointment of Jeremy Springhorn as a non-executive director.

·                  Voting Proposal No. 6: “FOR” designating the Boardappointment of Leonard Post as the competent body to issue Ordinary Shares and options and to exclude preemptive rights under the 2014 Restated Plan.a non-executive director.

·                  Voting Proposal No. 7: “FOR” the approval of the employee share purchase plan.

·                  Voting Proposal No. 8: “FOR” renewing the designation of the Board as the competent body to issue Ordinary Shares and optionsgrant rights to subscribe for Ordinary Shares.

·                  Voting Proposal No. 8: “FOR” reauthorizing the Board to exclude or limit preemptive rights upon the issuance of Ordinary Shares and granting of rights to limit or exclude preemptive rights.subscribe for Ordinary Shares.

·                  Voting Proposal No. 9: “FOR” reauthorization of the Board to repurchase Ordinary Shares.

·                  Voting Proposal No. 10: “FOR” reappointmentappointment of PricewaterhouseCoopersKPMG Accountants N.V. as external auditors of the Company’s independent registered public accounting firmCompany for the financial year 2018.2020.

·                  Voting Proposal No. 11: “FOR” on an advisory basis, the compensation of the named executive officers of the Company.

Voting by Proxy

The Ordinary Shares represented by any proxy duly given will be voted at the 20182020 Annual Meeting in accordance with the instructions of the Shareholder.  You may vote “FOR” or “AGAINST” or “ABSTAIN” from each of the proposals. If no specific instructions are given, the shares will be voted “FOR” the voting proposals described in this Proxy Statement.  In addition, if any other matters come before the 20182020 Annual Meeting, the persons named in the accompanying Proxy Card will vote in accordance with their best judgment with respect to such matters.

If we receive a signed and dated proxy card or receive your instructions by Internet or by telephone and your instructions do not specify how your shares are to be voted, your shares will be voted with the aforementioned Board’s recommendations.

Revoking Your Proxy

Even if you execute a proxy, you retain the right to revoke it and to change your vote, by notifyingor to attend and vote personally at the 2020 Annual Meeting or any adjournment thereof if you attend in person.  You must notify us at any time beforeof your intention to revoke your proxy is voted.no later than 6:00 p.m. Central European Summer Time on June 16, 2020. Such revocation may be effected in writing by execution of a subsequently dated proxy, or by a written notice of revocation, sent to the attention of Investor Relations at the address of our principal executive officeoffices set forth above, or by your attendance and voting in person at the 2018 Annual Meeting or any

adjournment thereof.above.  Unless so revoked, the shares represented by a proxy, if received in time, will be voted in accordance with the directions given therein.

If the 20182020 Annual Meeting is postponed or adjourned for any reason, at any subsequent reconvening of the 20182020 Annual Meeting, all proxies will be voted in the same manner as the proxies would have been voted at the original convening of the 20182020 Annual Meeting (except for any proxies that have at that time effectively been revoked or withdrawn).

You are requested, regardless of the number of shares you own or your intention to attend the 20182020 Annual Meeting, whether in person or over the Internet via live audio webcast, to vote by proxy as soon as possible by proxy.possible.  You do not need to affix postage to the enclosed reply envelope if you mail it within the United States.

Solicitation of Proxies

The expenses of solicitation of proxies will be paid by the Company. We may solicit proxies by mail, by electronic mail or by phone through agents of the Company.  Additionally, the employees of the Company, who will receive no extra compensation therefor, may solicit proxies personally, by telephone, electronic mail, facsimile or mail.  The Company will also reimburse banks, brokers or other institutions for their expenses incurred in sending proxies and proxy materials to the beneficial owners of shares held by them.

Delivery of Proxy Materials to Households

Only one copy of the Company’s 2017 Annual Report on Form 10-K (including the financial statements and schedules thereto) as filed with the Securities and Exchange Commission (the “SEC”) (the “2017 Annual Report”) and this Proxy Statement will be delivered to an address where two or more Shareholders reside unless we have received contrary instructions from a Shareholder residing at such address.  AUpon written or oral request from a Shareholder, we will promptly deliver a separate copy of the Annual Report on Form 10-K, the Proxy Statement, Notice of Internet Availability of Proxy Materials, and Proxy Card will be delivered to each Shareholder at the shared address.

If you are a Shareholder who lives at a shared address and you would like additional copies of the 2017 Annual Report on Form 10-K, the Proxy Statement, or any future annual reports or proxy statements, please contact InvestorsInvestor Relations, uniQure N.V., Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands, by telephone numberat +1-339-970-7000 or by email at investors@uniQure.com, and we will promptly mail you copies.  This Proxy Statement and the 2017 Annual Report on Form 10-K are also available at http://www.edocumentview.com/QURE.  If you are receiving multiple copies of this Proxy Statement and 2017the Annual Report on Form 10-K at your household and wish to receive only one, please contact Investor Relations at the mailing address, phone number or email address listed above.

Voting Results

The preliminary voting results will be announced at the 20182020 Annual Meeting. The final results will be disclosed in a Current Report on Form 8-K within four days after the meeting date.

Status as an “emerging growth company”

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups (JOBS) Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. These reduced reporting requirements include reduced disclosure about our executive compensation arrangements and no non-binding advisory votes on executive compensation. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of our initial public offering in February 2014, (b) in which we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

Contact for Additional Questions

If you hold your shares directly, please contact Investor Relations at uniQure N.V., Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands, by telephone numberat +1-339-970-7000, or by email at investors@uniQure.com. If your shares are held in street name, please use the contact information provided on your voting instruction form or contact your broker or other nominee holder directly.

AGENDA ITEM I—I

OPENING AND ANNOUNCEMENTS

The Chairman will open the 20182020 Annual Meeting and make any announcements.

AGENDA ITEM II —REPORT

REPORT ON THE FINANCIAL YEAR 20172019

This item is for discussion only.

Under this agenda item, the Board will discuss the business and results of operations of the Company as contained in the Dutch statutory annual report for the year ended December 31, 20172019 (the “2017“2019 Dutch Statutory Annual Report”). Our 20172019 Dutch Statutory Annual Report includes our consolidated financial statements for the year ended December 31, 2017,2019, for the uniQure N.V. group, which are comprised of the consolidated statements of financial position, consolidated statements of profit orand loss and other comprehensive income, consolidated statements of changes in equity and consolidated statements of cash flows with explanatory notes thereto prepared in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the European Union, as well as stand-alone Company-only financial statements of uniQure N.V. for the year ended December 31, 2017,2019, comprising uniQure N.V.’s Company-only statement of financial position and the Company-only statement of profit and loss with explanatory notes thereto prepared in accordance with Book 2 of the Dutch Civil Code (together “2017the “2019 Dutch Statutory Annual Accounts”), as well as the Report of the Board of Directors.

In accordance with the Dutch Corporate Governance Code, theThe contents of the corporate governance chapter in the 20172019 Dutch Statutory Annual Report, including the Company’s compliance with the Dutch Corporate Governance Code, will also be submitted for discussion.

AGENDA ITEM III —EXPLANATION

EXPLANATION OF THE APPLICATION OF THE REMUNERATION POLICY

This item is for discussion only.

Under this agenda item, and in accordance with the Dutch Civil Code, an explanation will be provided on how the Company’s remuneration policy was applied in fiscal year 2017.2019.

AGENDA ITEM IV

VOTING PROPOSAL NO. 1 —ADOPTION- ADOPTION OF THE 20172019 DUTCH STATUTORY ANNUAL ACCOUNTS

 AND TREATMENT OF THE RESULTS

As a public company with limited liability corporation (namenslooze vennopschaapnaamloze vennootschap) incorporated under the laws of the Netherlands, we are required by both Dutch law and our Articles of Association to prepare the Dutch statutory annual accounts and submit them to our shareholdersShareholders for confirmation and adoption. Our 20172019 Dutch Statutory Annual Accounts differ from the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2017,2019, that were prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and filed with the SEC. The 2017Our 2019 Dutch Statutory Annual Accounts contain some disclosures that are not required under U.S. GAAP and that are therefore not contained in our 20172019 Annual Report on Form 10-K.

A copy of our 20172019 Dutch Statutory Annual Accounts is available on our website at www.uniqure.com or may be obtained by contacting Investor Relations at investors@uniQure.com or by telephone numberat +1-339-970-7000.

Due to the international nature of our business and pursuant to a prior shareholder authorization, our 20172019 Dutch Statutory Annual Accounts have been prepared in the English language.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 20182020 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 1. Abstentions and broker-non votes will have no effect on the outcome of this vote.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE ADOPTION OF OUR DUTCH STATUTORY ANNUAL ACCOUNTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017.2019.

AGENDA ITEM V

VOTING PROPOSAL NO. 2—2 - DISCHARGE OF LIABILITY OF THE MEMBERS OF THE BOARD OF DIRECTORS

At the 20182020 Annual Meeting, as contemplated by Dutch law and as is typical for Dutch registered companies, our Shareholders will be asked to grant discharge of liability of the members of our Board in office for the management and conducted policy during the 20172019 financial year insofar as the exercise of such duties is reflected in the 20172019 Dutch Statutory Annual Report or otherwise disclosed to the 20182020 Annual Meeting.

If our Shareholders approve to grant discharge of liability, the members of our Board will not be liable to our Company for actions that such directors took on behalf of our Company in the exercise of their duties in 20172019 and as reflected in the 20172019 Dutch Statutory Annual Report or otherwise disclosed to the 20182020 Annual Meeting.  Therefore, this release does not apply to matters that were not previously disclosed to our Shareholders.  This release also is subject to the provisions of Dutch law relating to liability upon commencement of bankruptcy or other insolvency proceedings.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 20182020 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 2. Abstentions and broker-non votes will have no effect on the outcome of this vote.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE GRANT OF DISCHARGE OF LIABILITY OF THE MEMBERS OF OUR BOARD IN OFFICE DURING THE FISCAL YEAR ENDED DECEMBER 31, 20172019 FOR THE MANAGEMENT AND CONDUCTED POLICY DURING OUR FISCAL YEAR ENDED DECEMBER 31, 20172019 INSOFAR AS THE EXERCISE OF SUCH DUTIES IS REFLECTED IN THE 2019 DUTCH STATUTORY ANNUAL REPORT OR DISCLOSED TO THE 20182020 ANNUAL MEETING.

AGENDA ITEM VI

VOTING PROPOSAL NO. 3, and NO. 4, —NO. 5, AND NO. 6 - BOARD APPOINTMENTSAPPOINTMENT

The Board is responsible for establishing broad corporate policies and monitoring the overall performance of the Company.  It selects the Company’s senior management, delegates authority for the conduct of the Company’s day-to-day operations to those senior managers and monitors their performance.  Members of the Board are kept informed of the Company’s business by, among other things, participating in Board and Committee meetings and by reviewing analyses and reports provided to them.

The Board is currently made up of sevennine directors.  The termterms of office of onefour non-executive director, Philip Astley-Sparke, isdirectors, Jack Kaye, David Schaffer, Madhavan Balachandran and Jeremy Springhorn, are scheduled to expire on the date of the 20182020 Annual Meeting; the terms of office of three non-executive directors, Philip Astley-Sparke, David Meek, and Paula Soteropoulos, and one executive director, Robert Gut, are scheduled to expire on the date of the 2021 annual general meeting (the “2018 Annual Meeting”);of shareholders; and the term of office of one executive director, Matthew Kapusta, is scheduled to expire on the date of the 20192022 annual general meeting (the “2019 Annual Meeting”); the term of officeshareholders.  Under our Articles of four non-executiveAssociation, all directors Jack Kaye, David Schaffer, Madhavan Balachandran and Jeremy Springhorn, is scheduled to expire on the date of the 2020 annual meeting (the “2020 Annual Meeting”); and the term of office of one non-executive director, Paula Soteropoulos, is scheduled to expire on the date of the 2021 annual meeting (the “2021 Annual Meeting”).  All directors will hold office for a maximum term of four years, or until their earlier death, resignation, removalsuspension or disqualification.dismissal. However, the current practice of the Board is to nominate all directors, both executive and

non-executive, for terms of office of three years.  Our Board has implemented staggered terms to provide for a retirement schedule as required by our Articles of Association do not require the terms of the directors be staggered.Association.

The Board has nominated Philip Astley-SparkeMadhavan Balachandran for reelectionreappointment to the Board, to serve as a non-executive director until the 20212023 annual general meeting of shareholders or until his earlier death, resignation, removalsuspension or disqualification.dismissal. The Board has also nominated Robert GutJack Kaye for electionreappointment to the Board, to serve as a non-executive director until the 20212023 annual general meeting of shareholders or until his earlier death, resignation, removalsuspension or disqualification.

dismissal. The Board has nominated Jeremy Springhorn for reappointment to the Board, to serve as a non-executive director until the 2023 annual general meeting of Directors recommendsshareholders or until his earlier death, resignation, suspension or dismissal. The Board has nominated Leonard Post for appointment to the Board, to serve as a vote “FOR”non-executive director until the election2023 annual general meeting of eachshareholders or until his earlier death, resignation, suspension or dismissal. Each of Jack Kaye, Madhavan Balachandran, Jeremy Springhorn and Leonard Post has consented to being named in this Proxy Statement and to serve if appointed. Dr. Schaffer is not standing for reappointment to the nominees listed below.Board for another term.

The names, positionsname, position with the Company and agesage as of the Record Date of the individualsindividual who areis our nomineesnominee for electionappointment as directors are:a director is:

The Board may nominate an additional nominee between the date of the filing of this preliminary proxy and the date of the filing of the definitive proxy.  Should the Board do so, the Proxy Statement will be updated with information regarding the nominee and their anticipated role on the Board in the event the 2018 Annual Meeting approves his or her appointment.

PHILIP ASTLEY-SPARKE.MADHAVAN BALACHANDRAN  Philip Astley-Sparke,. Mr. Balachandran, age 46,69, has served as a member of our Board since June 2015 and as chairmanSeptember 2017. Mr. Balachandran has been a director of Catalent (NYSE: CTLT) since 2016. HeMay 2017.  Mr. Balachandran was previously presidentExecutive Vice President, Operations of uniQure Inc. from January 2013 until February 2015 and was responsible for building uniQure’s U.S. infrastructure. Mr. Astley-Sparke is currently Executive Chairman and co-founder of Replimune Group,Amgen Inc., a global biotechnology company, developing second-generation oncolytic vaccines.from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Astley-Sparke servedBalachandran joined Amgen in 1997 as vice presidentAssociate Director, Engineering. He became Director, Engineering in 1998, and, general managerfrom 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice President, Manufacturing. Prior to his tenure at Amgen, Inc. (NASDAQ: AMGEN)Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs Wellcome Company, a biopharmaceutical company, until December 2011, following Amgen’s acquisitionpredecessor before mergers of BioVex Group, Inc.,GlaxoSmithKline plc. Mr. Balachandran holds a biotechnology company,Master of Science degree in March 2011. Mr. Astley-Sparke had been PresidentChemical Engineering from The State University of New York at Buffalo and Chief Executive Officer of BioVex Group, which developed the first oncolytic vaccine to be approved in the western world following the approval of Imlygic in 2015. He oversaw the company’s relocation to the U.S.an MBA from the UK in 2005. Prior to BioVex, Mr. Astley-Sparke was a healthcare investment banker at Chase H&Q/Robert Fleming and qualified as a Chartered Accountant with Arthur Andersen in London. Mr Astley-Sparke has been a venture partner at Forbion Capital Partners, a life sciences venture capital fund, since May 2012 and serves as Chairman of the Board of Oxyrane, a biotechnology company.East Carolina University. We believe that Mr. Astley-SparkeBalachandran is qualified to serve as a non-executive directorNon-Executive Director due to his expertise andextensive experience in the biotechnology industry.

ROBERT GUT, M.D., PH.D.JACK KAYE. Dr. Robert Gut,Jack Kaye, age 54,76, has nearly 20 years of experience in the biopharmaceutical industry, leading clinical development and medical affairs initiatives in different therapeutic areas: endocrinology, hematology, inflammation, osteoporosis and women’s health. Dr. Gut was appointed the Chief Medical Officer of Versartis, Inc. in September 2017. Prior to joining Versartis, Dr. Gut served as Vice President, Global Medical Affairs and Development at Radius Health. Over the past decade, his contributions in regulatory activities have helped achieve six U.S. Food and Drug Administration (FDA) product approvals and three new product indications. He has supported the launch of nine new products, overseeing medical affairs activities, including medical science liaison team building, health economics and outcomes research, and market access. He has also served as a member of our Board since 2016. Mr. Kaye has also served as Chairman of the Advisory Committees for Reproductive Health DrugsAudit Committee of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) from 2006 to 2016 and Drug Safetyis currently chairman of the Audit Committee and Risk Management fora member of the FDA’s Center for Drug Evaluation and Research. For the majorityCompensation Committee of Dyadic International, Inc. (OTC: DYAI). Mr. Kaye began his career Dr. Gutat Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006. At Deloitte, he was responsible for servicing a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley matters. Prior to retiring, Mr. Kaye served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc. He headed the company’s U.S. Biopharm Medical organization with leading products in endocrinology, hemophilia and women’s health. He isPartner-in-Charge of Deloitte’s Tri-State Core Client practice, a recognized author ofposition he held for more than 90 publications20 years. Mr. Kaye has a Bachelor of Business Administration from Baruch College and is a member of numerous professional organizations, including The Endocrine Society (ENDO). Dr. Gut received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He has attended postgraduate programs and trainings at Wharton, Stanford and Harvard Business School.Certified Public Accountant. We believe that Dr. GutMr. Kaye is qualified to serve as a non-executive directorNon-Executive Director due to his expertiseextensive accounting and financial experience.

JEREMY SPRINGHORN, PH.D. Dr. Springhorn, age 57, has served as a member of our Board since September 2017. Since November 2017, Dr. Springhorn has been Chief Business Officer of Syros Pharmaceuticals (NASDAQ: SYRS), Inc. Prior to taking his position at Syros, Dr. Springhorn served as Partner, Corporate Development at Flagship Pioneering from March 2015 until June 2017 where he worked with VentureLabs in helping companies in various strategic and corporate development capacities and in creating next generation startups and with Flagship’s Corporate Limited Partners. Prior to joining Flagship, Dr. Springhorn was one of the original scientists at Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), where he played an integral role in its antibody engineering capabilities and was one of the original inventors of the drug Soliris®. At Alexion Pharmaceuticals, Dr. Springhorn was Vice President of Corporate Strategy and Business Development from 2006 until March 2015. Dr. Springhorn started at Alexion in 1992 where he served in various leadership roles in R&D before switching to Business Development in 2006. Prior to 1992, Dr. Springhorn received his Ph.D. from Louisiana State University Medical Center in New Orleans and his BA from Colby College. Dr. Springhorn currently serves on the Board of Directors for NMD Pharma, Board of Advisors for Mythic Therapeutics and the Board of Visitors for Colby College. We believe Dr. Springhorn is qualified to serve as a Non-Executive Director due to his extensive experience in the biotechnology industry.

LEONARD POST, PH.D. Dr. Post, age 67, has over 35 years of experience in the pharmaceutical industry where he has held various global executive positions and has extensive experience in research and development of product candidates. Since July 2016, Dr. Post has served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway, and is also Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology.  From February 2010 until June 2016, Dr. Post worked at BioMarin (NASDAQ: BMRN), in various positions including Chief Scientific Officer.   During that time he oversaw the initiation of BioMarin’s first gene therapy project for hemophilia A.  Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals.  He is also currently an advisor to Canaan Partners.  Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow.  He has a Bachelor of Science degree in Chemistry from the University of Michigan, and a Doctorate degree in Biochemistry from the University of Wisconsin.

Dr. GutPost has not previously served as a director or executive officer of the Company.

If elected, the terms of office for Mr. Astley-Sparke and Dr. Gut will expire on the date of the 2021 annual general meeting of shareholders.

Based upon information requested from and provided by each nominee for director concerning their background, employment and affiliations, including family relationships, our Board has determined that each of Mr. Astley-Sparke and Dr. Gut has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of the Nasdaq rules and the SEC.

If the 20182020 Annual Meeting approves the appointment of Dr. Gut to the Board,Post, the Board plans to appoint him to serve on the CompensationResearch and Development Committee. If appointed, the term of office of Dr. Post will expire on the date of the 2023 Annual General Meeting of Shareholders.  If reappointed, the term of office for each of Mr. Balachandran, Mr. Kay and Dr. Springhorn will expire on the date of the 2023 Annual General Meeting of Shareholders.

For information as to the Ordinary Shares held by Mr. Astley-Sparke,Balachandran, Mr. Kaye and Dr. Springhorn see “Security Ownership of Certain Beneficial Owners and Management.” Dr. Gut does not hold Ordinary Shares or options to purchase Ordinary Shares of the Company.

There are no arrangements or understandings between the nominees, directors or executive officers and any other person pursuant to which our nominees,nominee, directors or executive officers have been selected for their respective positions.  However, the Company has entered into indemnification agreements with its existing non-executive directors pursuant to which the Company agrees to indemnify such directors in certain circumstances.

VOTE REQUIRED

Consistent with Dutch law and our Articles of Association, executive directors and non-executive directors are appointed by a general meeting from a binding nomination by the non-executive directors. The affirmative vote of a majority of our Ordinary Shares,proposed candidate specified in the binding nomination shall be appointed, provided that the requisite quorum is present in person or represented by a proxy at the 20182020 Annual Meeting, unless the nomination is overruled by the general meeting (which would result if a majority of at least two-thirds of the votes cast, which majority represents more than half of the issued share capital, vote “against” the appointment or reappointment of such director, with abstentions, “blank votes”, “broker non-votes” and entitled to vote, is required to elect each director nominee. Each proposed non-executive director appointment isinvalid votes not considered a separate voting item under Dutch law.votes cast), in which case he or she will not be appointed.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THESETHE NOMINEES FOR DIRECTOR.

AGENDA ITEM VII

VOTING PROPOSAL NO. 5 — AMENDMENT OF THE 2014 RESTATED PLAN

The latest amendment of the 2014 Restated Plan was approved by the Company’s general meeting of shareholders on June 15, 2016. The purpose of the 2014 Restated Plan is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the group and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s shareholders. Pursuant to the 2014 Restated Plan, the Company may grant incentive share options, non-statutory share options, share appreciation rights, restricted share awards, restricted share units and other share-based awards. Under the 2014 Restated Plan, the maximum number of Ordinary Shares available is currently limited to 5,601,471. As of March 31, 2018, 823,897 Ordinary Shares remain available for grant under the 2014 Restated Plan.

Summary of 2014 Restated Plan

Pursuant to the 2014 Restated Plan, the Company may grant incentive share options, non-statutory share options, share appreciation rights, restricted share awards, restricted share units and other share-based awards. This summary is not intended to be complete and is qualified in its entirety by the 2014 Restated Plan filed as Exhibit 10.1 to our Form 10-K for the year ended December 31, 2017.

Share Options

The Board may grant options to purchase Ordinary Shares and determine the number of Ordinary Shares to be covered by each option, the exercise price of each option and the conditions and limitations applicable to the exercise of each option, including conditions relating to applicable securities laws, as it considers necessary or advisable. The Board shall establish the exercise price of each option and specify the exercise price in the applicable option agreement which shall be not less than 100% of the fair market value per ordinary share on the date the option is granted. Share options are granted on the date of grant and, except for certain grants made to non-executive directors, vest over a period of four years, the first 25% vests after one year from the initial grant date and the remainder vests in equal quarterly instalments, over years two, three and four. Certain grants to non-executive directors vest in full after one year. Any options that vest must be exercised by the tenth anniversary of the initial grant date, or within six months of ceasing to be an employee of the Company or otherwise being eligible to participate in the plan.

Restricted Share Units (“RSU”)

The Board may grant awards entitling the recipient to receive Ordinary Shares or cash to be delivered at the time such award vests. Restricted share units granted by the Company vest over one — three years. This includes grants made to non-executive directors vesting on the first anniversary of the grant date, grants offered as a retention element as part of the Company’s November 2016 restructuring, which vest after 15 — 26 months as well as grants vesting in equal annual instalments after the first, second and third anniversary of the grant date or in full on the third anniversary of the grant date. All of the above vesting is subject to the participant continuing to be employed by the Company or otherwise being eligible to participate in the plan.

Performance Share Units (“PSU”)

The Board may grant awards linked to specific performance criteria as determined by the Board and which will be earned based on the actual achievement of this specific criteria during the performance period, typically one year following the date of grant (known as the performance period), as determined by the Board.  The vesting period applicable to the PSUs will be set by the Board at the time of grant and is typically three years following the date of the grant.  Upon vesting of the PSUs, shares are automatically granted to the grantee.

Eligibility and Participation

All of the Company’s employees, executive directors and non-executive directors, as well as consultants and advisors to the Company (as such terms are defined and interpreted for purposes of Form S-8, or any successor form) are eligible to be granted awards under the Plan. Eligibility to participate in the Plan shall be determined at the sole discretion of the Board.

Termination of Status

The Board shall determine the effect on an award of the disability, death, termination or other cessation of employment, authorized leave of absence or other change in the employment or other status of a participant and the extent to which, and the period during which, the participant, or the participant’s legal representative, conservator, guardian or other designated beneficiary, may exercise rights under the award.

Acceleration

The Board may at any time provide that any award shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole or in part, as the case may be.

Reorganization Event

In connection with a Reorganization Event (as defined in the 2014 Restated Plan) where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Board determines otherwise, all outstanding awards that are not exercised or paid at the time of the Reorganization Event shall be assumed by, or replaced with awards that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). Unless the award agreement provides otherwise, if a participant’s employment or other service is terminated by the Company without cause (as determined by the Board) upon or within 12 months following a Reorganization Event, the participant’s outstanding awards shall become fully exercisable and any restrictions on such awards shall lapse as of the date of such termination; provided that if the restrictions on any such awards is based, in whole or in part, on performance, the applicable award agreement shall specify how the portion of the award that becomes vested shall be calculated in this situation.

In connection with a Reorganization Event, if all outstanding awards are not assumed by, or replaced with awards that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Board may take a number of different actions as detailed by the 2014 Restated Plan.

The Board has decided, in accordance with the discretion granted to it under the 2014 Restated Plan, that equity awards will vest in their entirety upon a Reorganization Event. Currently, all outstanding equity awards will vest on a Reorganization Event.

Tax Withholding

The participant must satisfy all applicable Dutch, United States and other applicable national, federal, state, and local or other income, national insurance, social and employment tax withholding obligations before the Company will deliver or otherwise recognize ownership of Ordinary Shares under an award. The Company may decide to satisfy the withholding obligations through additional withholding on salary or wages. If the Company elects not to or cannot withhold from other compensation, the participant must pay the Company the full amount, if any, required for withholding or have a broker tender to the Company cash equal to the withholding obligations. Payment of withholding obligations is due before the Company will issue any shares on exercise, vesting or release from forfeiture of an award or at the same time as payment of the exercise or purchase price, unless the Company determines otherwise. If provided for in an award or approved by the Board in its sole discretion, a participant may satisfy such tax obligations in whole or in part by delivery (either by actual delivery or attestation) of Ordinary Shares, including shares retained from the award creating the tax obligation, valued at their fair market value; provided, however, except as otherwise provided by the Board, that the total tax withholding where shares are being used to satisfy such tax obligations cannot exceed the Company’s minimum statutory withholding obligations (based on minimum statutory withholding rates for Dutch, United States and other applicable national, federal and state tax purposes, including payroll taxes, that are applicable to such supplemental taxable income). Shares used to satisfy tax withholding requirements cannot be subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.

Summary of Proposed Changes to the 2014 Restated Plan

It is now proposed to increase the equity incentive pool under the 2014 Plan in order to provide adequate incentives for new and existing employees, the executive director, non-executive directors, consultants and advisors in light of the significant growth of the group’s operations and staff to support the Company’s development programs. The amendment to the 2014 Restated Plan, if approved, will increase the authorized number of Ordinary Shares available by 3,000,000.

The material provisions of the amendment to the 2014 Restated Plan are summarized above. This description is not intended to complete and is qualified in its entirety by the Plan amendment, a copy of which is attached as Appendix A to this Proxy.

Historical Granting Practices

The Company’s granting practice during the years ended December 31, 2015, 2016 and 2017 was as follows:

(1)           Including new hire inducement awards to purchase 200,000 Ordinary Shares outside the 2014 Restated Plan;

(2)            Excluding the new hire inducement award to our former CEO Dan Soland to purchase 800,000 Ordinary Shares outside the 2014 Restated Plan;

(3)           Including new hire inducement awards to purchase 125,000 Ordinary Shares outside the 2014 Restated Plan;

(4)           Including new hire inducement awards to purchase 300,000 Ordinary Shares outside the 2014 Restated Plan;

(5)           Including new hire inducement awards for 175,000 Ordinary Shares outside the 2014 Restated Plan.

The above grants include the following grants made to the Board:

Rationale for Proposal to Increase Authorized Shares Under the 2014 Restated Plan

If the amendment to the 2014 Restated Plan is not approved, the Company will have only 823,897 Ordinary Shares available for future grants under the 2014 Restated Plan as of March 31, 2018. The Company continues to actively progress its clinical studies of AMT-061 in hemophilia B, AMT-130 in Huntington’s disease and AMT-126 in congestive heart failure, to support its collaboration with Bristol-Myers Squibb and to advance several preclinical product candidates for other liver and CNS-related disorders.  The Company believes that these activities, which may require additional hiring for the Company’s clinical, regulatory and medical teams, research and operational capabilities and corporate infrastructure, as well as retention and motivation of existing talent, are essential to achieving its corporate goals and generating shareholder value and require the continued use of equity-based compensation to retain current talent and to attract additional talent.

The Company anticipates that its equity-based compensation needs will soon exceed the remaining Ordinary Shares available under the 2014 Restated Plan. To address this concern, the Board unanimously recommends that the shareholders approve the proposed increase in authorized shares under the 2014 Restated Plan.

Key Considerations for Requesting Additional Shares Under the 2014 Restated Plan

In determining the increase in the number of Ordinary Shares available for issuance under the 2014 Restated Plan Plan, the Board considered the following factors:

·                                          Number of ordinary shares available for grant under the 2014 Restated Plan: As of March 31, 2018, 823,897 Ordinary Shares remained reserved and available for future grants under the 2014 Restated Plan.

·                                          Burn rate:  The Company’s burn rate is defined as the annual usage of shares for its equity plans, less forfeited and cancelled shares, as a percentage of its Ordinary Shares outstanding as of January 1 of the year.  In 2015, the Company’s burn rate was approximately 3.7%, (excluding the new-hire grant made to our former CEO in December 2015 who resigned in September 2016). In 2016 and 2017, the Company’s

burn rate was approximately 3.8% (excluding the forfeiture of the new hire grant of our former CEO in September 2016) and 5.9%, respectively.

The Company’s burn rate in 2017 was impacted by share grants associated with the appointment of several executives, including the CEO, Chief Medical Officer, Chief Operating Officer, Chief Scientific Officer and Senior Vice President, Regulatory Affairs.  Excluding these share grants, which included 625,000 options to purchase Ordinary Shares and 350,000 restricted share units, the burn rate in 2017 would have been 2.1%.

Based on the Company’s analysis of burn rates for peer companies, and feedback from independent specialists in executive compensation, the Company believes that its 2015-2017 burn rates are reasonably consistent with market practice.

·                                          Overhang: The Company’s overhang is defined the its options, performance share units and restricted share units outstanding as a percentage of all of its shares outstanding.  As of March 31, 2018, the Company had outstanding 2,940,293 options to purchase Ordinary Shares, 560,156 performance share units and 661,812 restricted share units. Based on the Company’s analysis of overhang for peer companies, and feedback from independent specialists in executive compensation, the Company believes that its overhang is reasonably consistent with market practice.

Dilution Analysis

As of March 31, 2018, the Company’s capital structure consisted of 31,771,816 Ordinary Shares outstanding. As described above, 823,897 Ordinary Shares remain available for grant of awards under the 2014 Restated Plan as of March 31, 2017. The proposed share authorization is a request for 3,000,000 additional Ordinary Shares to be available for awards under the 2014 Restated Plan.

The table below shows our potential dilution based on our fully diluted shares Ordinary Shares and our request for 3,000,000 additional Ordinary Shares to be available for awards under the 2014 Restated Plan. The additional 3,000,000 Ordinary Shares represent 7.5% of fully diluted Company Ordinary Shares, including all Ordinary Shares that will be authorized under the 2014 Restated Plan, as described in the table below. The Board of Directors believes that the increase in Ordinary Shares under the 2014 Restated Plan will allow the Company to continue providing equity awards, which are an important component of the Company’s equity compensation program, and represents a reasonable amount of potential equity dilution.

Total Potential Shares with 3,000,000 Additional Ordinary Shares

(1)The 1,221,968 Full Value Awards were comprised of: (a) 633,060 RSUs  granted to employees, (b) 560,156 PSUs granted to employees, (c) 28,752 RSUs granted to non-executive  directors.

(2)The 4,162,261 Total Equity Awards Outstanding were comprised of (a) 2,940,293 stock options outstanding as of March 31, 2018, (b) 633,060 RSUs  granted to employees, (c) 560,156 PSUs granted to employees, (d) 28,752 RSUs granted to non-executive  directors.

The Fully Diluted Ordinary Shares in the foregoing table consist of the Ordinary Shares Outstanding as of March 31, 2018 plus the Total Potential Shares under the 2014 Restated Plan, as amended (and all predecessor employee and non-employee director equity compensation plans). The Outstanding Full Value Awards in the foregoing table are measured at target for the outstanding performance-based awards.

Based on our current equity award practices, the Board of Directors estimates that the authorized shares under the 2014 Restated Plan as amended may be sufficient to provide us with an opportunity to grant equity awards for approximately two to three years, in amounts determined appropriate by the Board, which will administer the 2014 Restated Plan as amended. This is only an estimate, and circumstances could cause the share reserve to be used more quickly or more slowly. These circumstances include, but are not limited to, the future price of our common stock, the mix of cash, options and full value awards provided as long-term incentive compensation, grant amounts provided by our competitors, payout of performance-based awards in excess of target in the event of superior performance, hiring activity, and promotions during the next few years.

Amendment to the 2014 Restated Plan

The Company is committed to strong corporate governance and maximizing shareholder value. The Board believes the use of equity-based compensation aligns plan participants’ interests with shareholders, and thereby promotes best practices in corporate governance. To this end, the Board proposes the following amendment to the 2014 Restated Plan:

·                                         Increase the number of Ordinary Shares reserved for issuance, so that the number of shares reserved for issuance is 7,322,340 shares, which is equal to the sum of (i) 3,498,443 Ordinary Shares subject to outstanding awards under the 2014 Restated Plan, plus (ii) 823,897 Ordinary Shares remaining available for future grants under the 2014 Restated Plan, and (iii) an increase of 3,000,000 Ordinary Shares over the current authorization of the 2014 Restated Plan that will be available for awards under the 2014 Restated Plan.

In determining the appropriate number of shares to request, the Board analyzed market practices of peer companies and solicited advice from independent specialists in executive compensation. Upon a review of the remaining shares available for grant under the 2014 Restated Plan and the anticipated need for future equity award issuances, the Board approved the increase in the ordinary share pool authorized for issuance, to ensure that the Company has sufficient equity plan capacity to continue to provide its management, employees and directors with appropriate equity-based incentives.

The Board believes that the increase in the authorized number of Ordinary Shares under the 2014 Restated Plan is essential to ensure that the Company has a sufficient reserve to grant equity incentives at levels deemed appropriate by the Compensation Committee and the Board. The Company believes that competitive equity awards are important in attracting and retaining talent as the Company progresses its clinical and preclinical product candidates. Without the increase in the authorized shares under the 2014 Restated Plan, the Company may not be able to retain and motivate current talent or to attract additional talent that may needed to achieve its corporate goals, and may be required to provide significantly higher cash compensation. The Board is also committed to supporting best practices in corporate governance and believes that the proposed changes to the 2014 Restated Plan reflect best practices. These amendments better align the features and design of the 2014 Restated Plan with the Company’s goal of maximizing and preserving shareholder value.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares, present in person or represented by proxy at the 2018 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 5.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE AMENDMENT FOR THE 2014 RESTATED PLAN.

AGENDA ITEM VIII

VOTING PROPOSAL NO. 6 — DESIGNATION OF THE BOARD AS THE COMPETENT BODY TO ISSUE ORDINARY SHARES AND OPTIONS AND TO EXCLUDE PREEMPTIVE RIGHTS UNDER THE 2014 RESTATED PLAN

At the annual general meeting of shareholders held on June 15, 2016, the shareholders designated the Board as the competent body to issue Ordinary Shares and options under the 2014 Restated Plan, and to exclude pre-emptive rights in connection therewith. It is proposed that the Board is designated as the competent body to issue Ordinary Shares and to grant rights to subscribe for Ordinary Shares under the 2014 Restated Plan, as amended, for the duration of the 2014 Restated Plan with effect from the date of the 2018 Annual Meeting, and to limit or exclude pre-emption rights in connection therewith. This authority is limited to a maximum of 8,601,471 Ordinary Shares. It is further proposed to the AGM to approve that this maximum number of Ordinary Shares be reserved for issuance under and pursuant to the 2014 Restated Plan.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares, present in person or represented by proxy at the 2018 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 6.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE DESIGNATION OF THE BOARD AS THE COMPETENT BODY TO ISSUE ORDINARY SHARES AND OPTIONS AND TO EXCLUDE PREEMPTIVE RIGHTS UNDER THE 2014 RESTATED PLAN.

AGENDA ITEM IX

VOTING PROPOSAL NO. 7 — APPROVAL OF EMPLOYEE SHARE PURCHASE PLAN

The shareholders are being asked to approve the adoption of the uniQure N.V. Employee Stock Purchase Plan (the “Purchase Plan”), under which 150,000 of the Company’s Ordinary Shares will be reserved for issuance, subject to adjustments in certain circumstances described below. The Purchase Plan is expected to be adopted by the Board on April 27, 2018, subject to shareholder approval of the Purchase Plan at the 2018 Annual Meeting.

The Purchase Plan is designed to allow eligible employees of the Company and its designated subsidiaries (whether now existing or subsequently established or acquired) to purchase Ordinary Shares at designated intervals through their accumulated payroll deductions.  The provisions of the Purchase Plan are intended to satisfy the requirements of Section 423 of the U.S. Internal Revenue Code of 1986, as amended (“Internal Revenue Code”) with respect to U.S. participants. Favourable tax treatment is available for U.S. tax residents participating in a plan that qualifies under Section 423 of the Code. See “U.S. Federal Income Tax Considerations” below. We are asking the shareholders to approve the Purchase Plan because we believe that the Purchase Plan is important to attract, motivate and retain highly-qualified employees who will contribute to our long-term success. We believe that providing our employees with a convenient method to invest in our Ordinary Shares will increase the equity stake of our employees and will benefit the shareholders by aligning more closely the interests of participating employees with those of our shareholders.

The following is a summary of the principal features of the new Purchase Plan. The summary, however, is not intended to be a complete description of all the provisions of the Purchase Plan and is qualified in its entirety by reference to the complete text of the Purchase Plan. A copy of the actual Purchase Plan is attached as Appendix B to this Proxy Statement.

Administration

The Purchase Plan will be administered by the Compensation Committee of the Board or such other committee that the Board appoints to administer the Purchase Plan (the “Committee”). The Committee will have full discretionary authority to construe and interpret the Purchase Plan, adopt, amend and rescind any rules as it deems desirable and appropriate, and to make all other determinations necessary or advisable for the administration of the Purchase Plan. The Committee, in its discretion, may appoint and remove the plan coordinator designated to handle administrative matters with respect to the Purchase Plan, and may delegate such administrative or ministerial duties to the plan coordinator as it determines. The Board may take all actions that the Committee may take hereunder, at the Board’s discretion. The Committee will have the authority to authorize one or more offerings under the Purchase Plan that are not designed to comply with the requirements of Section 423 of the Code, but with the requirements of the jurisdictions in which those offerings are conducted. Such offerings will be separate from any offerings designed to comply with Section 423(b)(5) of the Code.

Eligibility

To be eligible to participate in the Purchase Plan, an employee must be customarily employed at least 20 hours per week (and work more than five months in a calendar year) by the Company or a subsidiary of the Company designated by the Committee as eligible to participate in the Purchase Plan. As of March 31, 2018, approximately 187 employees, including 6 executive officers, would have been eligible to participate in the Purchase Plan had it been in effect on such date.

No employee may be granted an option under the Purchase Plan if (i) immediately after the grant, that employee would own shares or hold outstanding options to purchase shares possessing in the aggregate 5% or more of the total combined voting power or value of all classes of our shares, or (ii) the option, together with any rights to purchase shares under all of our employee stock purchase plans (as described in Section 423 of the Code), would permit the employee’s rights to purchase shares to accrue at a rate that exceeds the maximum amount allowed under Section 423(b)(8) of the Code.

Offering Periods and Purchase Periods

The Purchase Plan will have offering periods and each offering period will consist of one or more consecutive purchase periods, each as determined by the Committee. Unless the Committee determines otherwise before the beginning of an offering period, offering periods will commence at three-month intervals on each March 1, June 1, September 1 and December 1 and last for three months. Unless the Committee determines otherwise before the beginning of a purchase period, purchase periods will run concurrently with the offering periods under the Purchase Plan. The maximum offering period under the Purchase Plan is 27 months. The initial offering period under the Purchase Plan will commence on September 1, 2018.

Participation

Each eligible employee who elects to participate in an offering period will be granted an option to purchase Ordinary Shares on the first day of the offering period. A participant may fund his or her contributions to the Purchase Plan by payroll deductions during the offering period or other funding methods approved by the Committee. Unless the Committee determines otherwise or as required by applicable law, a participant may not increase or decrease the rate of his or her contributions during the offering period. The option will automatically be exercised on the last day of each purchase period within the offering period, based on the employee’s accumulated and unused contributions, and the Company will arrange for delivery of the shares to the participant’s brokerage account that we establish for the participant at a brokerage firm that we designate (“Purchase Plan Brokerage Account”). The last day of the purchase period is the purchase date. For purposes of the Purchase Plan, compensation is a participant’s base salary or base wages, and payments of commissions, overtime, incentive compensation and bonuses.

Cessation of Participation

Participants may stop their participation in an offering period under the Purchase Plan at any time prior to the purchase date and withdraw all (but not less than all) contributions credited to his or her account. A participant who elects to cease participation in the Purchase Plan for a particular offering period may not rejoin that offering period at a later date. Participation ends automatically if the participant ceases to be an eligible employee for any reason, including without limitation, voluntary or involuntary termination of employment, retirement or death. In addition, unless the Committee determines otherwise, in the event that more than 50% of our shares entitled to vote for the election of our directors are acquired by a third party, we sell all or substantially all of our assets or property or we merge with another corporation resulting in our shareholder owning less than 51% of our capital shares entitled to vote for our directors, no outstanding option will be exercised, all participant contributions will cease and contributions credited to participant accounts will be returned to the participants.

Maximum Number of Purchasable Shares

The maximum number of shares that a participant may purchase during an offering period may not exceed 1,750 shares, subject to adjustment by the Committee prior to the beginning of the applicable offering period. In addition, no participant may purchase more than the maximum allowed under Section 423(b)(8) of the Code, which is $25,000 of Ordinary Shares during any calendar year under the Purchase Plan, measured as of the first day of each offering period in that year.

Securities Subject to the Purchase Plan

Subject to adjustment described below, the number of the Company Ordinary Shares reserved for issuance under the Purchase Plan will initially be 150,000 shares. In the event of a stock split, reverse stock split, stock dividend, combination or reclassification of Ordinary Shares, or any other increase or decrease in the number of Ordinary Shares effected without our receipt of consideration, the Committee will adjust the number of Ordinary Shares covered by each outstanding option under the Purchase Plan, the number of Ordinary Shares which has been authorized for issuance under the Purchase Plan and the price per Ordinary Share covered by each outstanding option under the Purchase Plan. In the event of a reorganization, recapitalization, rights offering, merger, or consolidation, the Committee may, in its sole discretion, adjust the number of Ordinary Shares which has been authorized for issuance under the Purchase Plan and the price per Ordinary Share covered by each outstanding option under the Purchase Plan.

Share Pro-Ration

Should the total number of Ordinary Shares to be purchased pursuant to outstanding options on any particular purchase date exceed the number of shares then available for issuance under the Purchase Plan, then the Company will make a pro-rata allocation of the available shares on a uniform and equitable basis, and the payroll deductions of each participant will be reduced to the extent necessary.

Purchase Price

The purchase price of the Ordinary Shares acquired on each purchase date will be the lesser of (a) 85% of the closing price of an Ordinary Share on the first day of the offering period or (b) 85% of the closing price of an Ordinary Share on the purchase date. Participants will incur no brokerage or other transaction costs upon the purchase of Ordinary Shares through the Purchase Plan.

On March 29, 2018, the closing price per Ordinary Share was $23.50 per share, as reported by the NASDAQ Global Select Market.

Restrictions on Sale and Transfers.

The shares purchased by each participant will be deposited into the participant’s Purchase Plan Brokerage Account.  Unless the shares are sold, the shares must be held in that brokerage account until the later of the end of the two-year

period from the start date of the offering period in which the shares were purchased and the end of the one-year period measured from the purchase date.  Unless the shares are sold, the shares in the Purchase Plan Brokerage Account are not transferable until the holding periods described above have expired.  Subject to compliance with applicable law, the Committee may require that shares acquired under the Purchase Plan be held for a period of up to 12 months following the purchase date.  If the Committee implements such a restriction, it will not apply in the event of a participant’s death to the transfer of shares to the participant’s estate or the subsequent shale of the shares by the estate.

Contributions credited to a participant’s account and any rights with regard to the exercise of an option or to receive shares under the Purchase Plan may not be assigned, transferred, pledged or otherwise disposed of in any way by the participant.

Use of Funds

All contributions received or held by the Company under the Purchase Plan are general assets of the Company, free of any trust or other restriction, and may be used by the Company for any corporate purpose, and the Company will not be obligated to segregate such contributions. Participants’ accounts under the Purchase Plan are unfunded bookkeeping accounts maintained on the Company’s records for the administration of the Purchase Plan.

Reports

Each participant in the Purchase Plan will be entitled to a statement of account promptly following each purchase date, setting forth with respect to that purchase period the amount of contributions, the per share purchase price, the number of shares purchased and the remaining cash balance, if any.

Amendment and Termination of the Purchase Plan

The Board may at any time amend or terminate the Purchase Plan. However, shareholder approval is required to the extent required under Section 423 of the Code, including for any amendment that increases the number of shares reserved under the Purchase Plan (other than an increase to reflect a change in capitalization) or change the designation of corporations whose employees may be offered options under the Purchase Plan. The Purchase Plan shall terminate on June 12, 2028, unless terminated earlier by our Board at its discretion or because all reserved shares have been issued under the Purchase Plan.

Shareholder Rights

No participant will have any shareholder rights with respect to the shares covered by his or her options until the shares are actually purchased on the participant’s behalf and the participant has become a holder of record of the purchased shares.

New Plan Benefits

The benefits to be received by our executive officers and employees under the Purchase Plan are not determinable because, under the terms of the Purchase Plan, the amounts of future share purchases are based upon elections made by eligible employees subject to the terms and limits of the Purchase Plan.  Members of the Board who are not employees do not qualify as eligible employees and thus cannot participate in the Purchase Plan.  Future purchase prices are not determinable because they will be based upon the closing selling price of our Ordinary Shares.  No Ordinary Shares have been issued with respect to the Purchase Plan for which shareholder approval is being sought under this proposal.

Summary of U.S. Federal Income Tax Consequences

The following is a brief description of the U.S. federal income tax consequences generally arising with respect to Ordinary Shares that may be purchased pursuant to options granted under the Purchase Plan. This description of the U.S. federal income tax consequences of the Purchase Plan is not a complete description. There may be different tax consequences under certain circumstances, and there may be federal gift and estate tax consequences and state, local and foreign tax consequences. All affected individuals should consult their own advisors regarding their own situation. This discussion is intended for the information of the shareholders considering how to vote at the 2018 Annual Meeting and not as tax guidance to individuals who will participate in the Purchase Plan.

The Purchase Plan is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Code. Under a plan which so qualifies, no taxable income will be recognized by a participant, and no deductions will be allowable to the Company, upon either the grant or the exercise of the options. Taxable income will not be recognized until there is a sale or other disposition of the shares acquired under the Purchase Plan or in the event the participant should die while still owning the purchased shares.

If the participant sells or otherwise disposes of the purchased shares within two years after the start date of the offering period in which such shares were acquired or within one year after the purchase date of those shares, then the participant will recognize ordinary income in the year of sale or disposition equal to the amount by which the fair market value of the shares on the purchase date exceeded the purchase price paid for those shares, and the Company will be entitled to an income tax deduction, for the taxable year in which such sale or disposition occurs, equal in amount to such excess. The participant will have additional capital gain or loss equal to the difference between the proceeds of the sale and the participant’s basis in the shares sold. The participant’s basis in the shares sold is equal to the price paid for the shares plus the amount of any ordinary income recognized on the sale. The capital gain rate will depend on the length of time the participant held the shares.

If the participant sells or disposes of the purchased shares more than two years after the start date of the offering period in which the shares were acquired and more than one year after the purchase date of those shares, then the participant will recognize ordinary income in the year of sale or disposition equal to the lesser of (i) the amount by which the fair market value of the shares on the sale or disposition date exceeded the purchase price paid for those shares or (ii) 15% of the fair market value of the shares on the start date of that offering period, and any additional gain (or loss) upon the disposition will be taxed as a long-term capital gain (or loss). The Company will not be entitled to an income tax deduction with respect to such sale or disposition.

If the participant still owns the purchased shares at the time of death, then the participant will recognize ordinary income at such time equal to the lesser of (i) the amount by which the fair market value of the shares on the date of death exceeds the purchase price or (ii) of the amount by which the fair market value of the shares on the start date of the offering period in which those shares were acquired exceeds the purchase price.

Dilution

When determining the number of shares available for issuance under the Purchase Plan, the Board considered, among other factors, its expectation of potential future share purchases under the Purchase Plan and the potential dilution of the Purchase Plan to the Company’s current shareholders. The Board determined that reserving 150,000 Ordinary Shares for the Purchase Plan was appropriate by considering, among other factors, activity under the Company’s prior employee stock purchase plan and its expectation that there would be significant participation by employees in this Purchase Plan.

The 150,000 Ordinary Shares available for issuance under the Purchase Plan represent dilution of approximately 0.5% as of March 31, 2018. The dilution is calculated as the ratio of: (a) shares available for issuance under the Purchase Plan; divided by (b) the sum of (i) the number of Ordinary Shares outstanding and (ii) the Ordinary Shares available for issuance under the Purchase Plan.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares, present in person or represented by proxy at the 2018 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 7.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE APPROVAL OF THE EMPLOYEE SHARE PURCHASE PLAN.

AGENDA ITEM X

VOTING PROPOSAL NO. 8—- RENEW THE DESIGNATION OF THE BOARD AS THE COMPETENT BODY TO ISSUE ORDINARY SHARES AND OPTIONS ANDGRANT RIGHTS TO LIMIT OR EXCLUDE PREEMPTIVE RIGHTSSUBSCRIBE FOR ORDINARY SHARES

At the 20182020 Annual Meeting, as contemplated by Dutch law and as is typical for Dutch registered companies, our shareholdersShareholders will be asked to: (i) redesignateto renew the designation of our Board as the competent body to issue Ordinary Shares and to grant rights to subscribe for Ordinary Shares up to a maximum of (i) our authorized share capital in the event of an underwritten public offering, or (ii)  a maximum of 19.9% of our aggregate issued share capital at the time of issuance in connection with any other single issuance (or series of related issuances), for a term of 18 months with effect from the date of the 20182020 Annual Meeting, and (ii) renew the authority of our Board to limit or exclude pre-emptive rights in connection therewith.  This authority to issue authorized shares and exclude pre-emptive rights is similar to that generally afforded under state law to boards of directors of companies domiciled in the United States.Meeting.

Our current authorized share capital consists of 60,000,000 Ordinary Shares, each with a nominal value per share of €0.05.  Under Dutch law and our Articles of Association, we are required to seek the approval of our shareholdersShareholders each time we wish to issue shares of our authorized ordinary share capital unless our shareholdersShareholders have authorized our Board to issue shares.  This authorization may not continue for more than five years but may be given on a rolling basis.  We currently have authorization from our shareholdersShareholders to issue Ordinary Shares, or grant rights to subscribe for Ordinary Shares, up to a maximum of (i) our authorized share capital in the event of an underwritten public offering or (ii)  a maximum of 19.9% of the Company’sour aggregate issued share capital at the time of issuance in connection with any other single issuance (or series of related issuances).  This existing authorization expires on December 14, 2018,19, 2020, and it is common practice for Dutch companies to seek to renew this authorization annually on a rolling basis.  The approval of this voting proposal will maintain our flexibility to allow our Board to issue ourOrdinary Shares and to grant rights to subscribe for Ordinary Shares without the delay and expense of calling extraordinary general meetings of shareholders. The designation can be used for any and all purposes, including any issuance under the Purchase Plan, subject to statutory limitations, and with the exception of awards granted under the 2014 Amended and Restated Share Option Plan.

We also currently issue Ordinary Shares from our authorized share capital to satisfy our obligations under awards granted under our equity compensation plans, and the Shareholders have separately authorized such plans.  Other than ordinary share issuances in connection with our equity compensation plans and the ordinary shares that we may sell as part of our “at the market” programany sales deemed to be “at-the-market offerings” pursuant to our supplemental prospectus filed on March 2, 2020 with the Sale Agreement dated September 15, 2017 between Leerink Partner LLCUnited States Securities and us,Exchange Commission, we do not have any specific plans, proposals, or arrangements to issue any of our authorized Ordinary Shares for any purpose.  However, in the ordinary course of our business, our Board may determine from time to time that the issuance of authorized and unissued shares is in the best interests of our Company, including in connection with equity compensation or future acquisitions or financings.

Under Dutch law, holders of our Ordinary Shares would generally have a pro rata pre-emptive right of subscription to any of our ordinary shares issued for cash. A pre-emptive right of subscription is the right of our current shareholders to maintain their percentage ownership of our ordinary shares by buying a proportional number of any new ordinary shares that we issue. However, Dutch law and our Articles of Association permit our shareholders to authorize our Board to exclude or restrict these pre-emptive rights. This authorization may not continue for more than five years, but may be given on a rolling basis. We currently have authorization from our shareholders to exclude or restrict these pre-emptive rights, which authorization expires on December 14, 2018, and it is common practice for Dutch companies to seek to renew this authorization annually on a rolling basis.

At the 2018 Annual Meeting, we are asking our shareholders to renew the authority of our Board to issue our Ordinary Shares, grant rights to purchase or subscribe for our unissued Ordinary Shares up to a maximum of (i) our authorized share capital in the event of an underwritten public offering, or (ii) a maximum of 19.9% of our aggregate

issued capital at the time of issuance in connection with any other single issuance (or series of related issuances), from time to time, and exclude or limit pre-emptive rights in connection therewith, both for a term of 18 months with effect from the date of the 2018 Annual Meeting.  This authority to issue shares is similar to that generally afforded under state law to the boards of directors of public companies domiciled in the United States. Management believes that retaining the flexibility to allow our Board to issue our Ordinary Shares for acquisitions, financings or other business purposes in a timely manner without first obtaining specific shareholder approval is important to our continued growth.  Furthermore, our Ordinary Shares are listed on the NASDAQNasdaq Global Select Market, and the issuance of additional shares will remain subject to Nasdaq

rules.  For example, one of the Nasdaq rules requires shareholder approval for the issuance of shares in a private placement in excess of 20% of the shares outstanding, with several exceptions.

If our shareholdersShareholders do not redesignaterenew the designation of our Board as the competent body to issue Ordinary Shares and to grant rights to subscribe for Ordinary Shares, on the terms set forth above, then the previous authorization would remain in place, and our Board would continue to retain authority to issue our Ordinary Shares and to grant rights to subscribe for our Ordinary Shares pursuant to that authorization until it expires on December 14, 2018.19, 2020.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 20182020 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 8.7. Abstentions and broker-non votes will have no effect on the outcome of this vote.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE RENEWAL OF THE AUTHORITY OF OUR BOARD TO ISSUE OUR ORDINARY SHARES AND GRANT RIGHTS TO PURCHASE OR SUBSCRIBE FOR OUR UNISSUED ORDINARY SHARES UP TO A MAXIMUM OF (I) OUR AUTHORIZED SHARE CAPITAL ANDIN THE EVENT OF AN UNDERWRITTEN PUBLIC OFFERING OR (II) 19.9% OF OUR AGGREGATE ISSUED SHARE CAPITAL AT THE TIME OF ISSUANCE IN CONNECTION WITH ANY OTHER SINGLE ISSUANCE (OR SERIES OF RELATED ISSUANCES), FOR A TERM OF 18 MONTHS WITH EFFECT FROM THE DATE OF THE 2020 ANNUAL MEETING.

AGENDA ITEM VIII

VOTING PROPOSAL NO. 8 - REAUTHORIZE THE BOARD TO EXCLUDE OR RESTRICTLIMIT PREEMPTIVE RIGHTS UPON THE ISSUANCE OF ORDINARY SHARES AND GRANTING OF RIGHTS TO SUBSCRIBE FOR ORDINARY SHARES

Under Dutch law, holders of our Ordinary Shares would generally have a pro rata pre-emptive right of subscription to any of our Ordinary Shares issued for cash. A pre-emptive right of subscription is the right of our current Shareholders to maintain their percentage ownership of our Ordinary Shares by buying a proportional number of any new Ordinary Shares that we issue. However, Dutch law and our Articles of Association permit our Shareholders to authorize our Board to exclude or limit these pre-emptive rights. This authorization may not continue for more than five years, but may be given on a rolling basis. We currently have authorization from our Shareholders to exclude or limit these pre-emptive rights, which authorization expires on December 19, 2020, and it is common practice for Dutch companies to seek to renew this authorization annually on a rolling basis.

At the 2020 Annual Meeting, we are asking our Shareholders to renew the authority of our Board to exclude or limit pre-emptive rights in relation to our Ordinary Shares and rights to subscribe for our Ordinary Shares in connection with the issuance or granting thereof for a term of 18 months with effect from the date of the 2020 Annual Meeting.

If our Shareholders do not renew the authority of our Board to exclude or limit preemptive rights in relation to our Ordinary Shares and rights to subscribe for our Ordinary Shares on the terms set forth above, then the previous authorization would remain in place, and our Board would continue to retain authority to exclude or limit preemptive rights to subscribe for our Ordinary Shares pursuant to that authorization until it expires on December 19, 2020.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 2020 Annual Meeting and entitled to vote, or the affirmative vote of a two-thirds majority of our Ordinary Shares present in person or represented by proxy at the 2020 Annual Meeting and entitled to vote if only less than half of the issued share capital is so present or represented at the 2020 Annual Meeting, is required to approve Voting Proposal No. 8. Abstentions and broker-non votes will have no effect on the outcome of this vote.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE AUTHORITY OF THE BOARD TO EXCLUDE OR LIMIT PRE-EMPTIVE RIGHTS FROM TIME TO TIME, FOR A TERM OF 18 MONTHS WITH EFFECT FROM THE DATE OF THE 20182020 ANNUAL MEETING.

AGENDA ITEM XIIX

VOTING PROPOSAL NO. 9—REAUTHORIZATION OF9 - REAUTHORIZE THE BOARD TO REPURCHASE ORDINARY SHARES

At the 20182020 Annual Meeting, as contemplated by Dutch law and as is typical for Dutch registered companies, our shareholdersShareholders will be asked to authorize our Board to acquire the Company’s own fully paid-up Ordinary Shares up to a maximum of 10% of the issued share capital of the Company for a period of 18 months from the date of the 20182020 Annual Meeting in open market purchases, through privately negotiated transactions, or by means of self-tender offer or offers, at prices per share ranging from the nominal value up to 110% of the market price per share at the time of the transaction.  This authority to repurchase shares is similar to that generally afforded under state law to public companies domiciled in the United States.  For purposes of this authorization, “market price” means the highest price officially quoted for the Ordinary Shares on any of the official stock markets on which the Ordinary Shares are listed during any of the 30 banking days preceding the date the repurchase is effected or proposed. Our Ordinary Shares are currently listed on the Nasdaq Global Select Market. The current authorization of our Board to repurchase sharesOrdinary Shares is scheduled to expire on December 14, 2018.19, 2020.

Under Dutch law and our Articles of Association, our Board may, subject to certain Dutch statutory provisions, be authorized to repurchase our issued sharesOrdinary Shares on our behalf in an amount, at prices and in the manner authorized by the general meeting of shareholders.  Adoption of this voting proposal will allow us to have the flexibility to repurchase our sharesOrdinary Shares without the expense of calling an extraordinary general meeting of shareholders.  Such authorization may not continue for more than 18 months, but may be given on a rolling basis.  Although our Board has no present intention to commence an open market or other share repurchase program, our Board believes that we would benefit by authorizing our Board to repurchase our sharesOrdinary Shares if the Board believes such repurchases would be in theour and our Shareholders’  best interests of our company and shareholders.interests.  For example, to the extent our Board believes that our sharesOrdinary Shares may be undervalued at the market levels at which they are then trading, repurchases of our share capital may represent an attractive investment for us. Such sharesOrdinary Shares could be used for any valid corporate purpose, including use under our equity compensation plans, or for acquisitions, mergers or similar transactions.  The reduction in our issued capital resulting from any such purchases will increase the proportionate interest of the remaining shareholders in our net worth and whatever future profits we may earn.  However, the number of sharesOrdinary Shares repurchased, if any, and the timing

and manner of any repurchases would be determined by our Board, in light of prevailing market conditions, our available resources and other factors that cannot be predicted now.  The nominal value of the sharesOrdinary Shares in our issued share capital whichthat we acquire, hold, hold as pledgee or which are acquired or held by one of our subsidiaries, may never exceed 50% of our issued share capital.

In order to provide us with sufficient flexibility, our Board proposes that our Shareholders authorize our Board for an 18-month period from the date of the 20182020 Annual Meeting to acquire the Company’s own fully paid-up Ordinary Shares up to a maximum of 10% of the issued share capital of the Company on thein open market orpurchases, through privately negotiated repurchasestransactions or inby means of self-tender offer or offers, at prices ranging from the nominal value up to 110% of the market price per share at the time of the transaction, within the limits set by Dutch law and the Company’sour Articles of Association.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 20182020 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 9. Abstentions and broker-non votes will have no effect on the outcome of this vote.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS VOTE “FOR” THE AUTHORIZATION OF THE BOARD TO REPURCHASE FULLY PAID UP ORDINARY SHARES UP TO 10 %10% OF THE ISSUED SHARE CAPITAL FOR A PERIOD OF 18 MONTHS FROM THE DATE OF THE 20182020 ANNUAL MEETING AT A REPURCHASE PRICE BETWEEN THE NOMINAL VALUE OF THE ORDINARY SHARES CONCERNED AND AN AMOUNT EQUAL TO 110% OF THE MARKET PRICE PER SHARE AT THE TIME OF THE PURCHASE.

REPORT OF THE AUDIT COMMITTEE

The report of the Audit Committee is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, both as amended.

The Audit Committee of our Board is responsible for assisting the Board in fulfilling its oversight responsibilities regarding the Company’s financial accounting and reporting processes, system of internal control, audit process, and process for monitoring compliance with laws and regulations.

Management of the Company has the primary responsibility for preparing the Company’s consolidated financial statements, as well as establishing and maintaining the integrity of the Company’s financial reporting process, accounting principles and internal controls.  PricewatershouseCoopers AccountsKPMG Accountants N.V., the Company’s independent registered public accounting firm isfor the 2019 financial year, was responsible for performing an audit of the Company’s consolidated financial statements and expressing an opinion as to the conformity of such financial statements with U.S. generally accepted accounting principles.

In this context, the Audit Committee reviewed and discussed the audited financial statements of the Company as of and for the year ended December 31, 20172019 with the Company’s management and PricewatershouseCoopers AccountsKPMG Accountants N.V.  To ensure independence, the Audit Committee met separately with PricewatershouseCoopers AccountsKPMG Accountants N.V. and members of the Company’s management.  These reviews included discussion with the independent registered public accounting firm of matters required to be discussed pursuant to Statement on Auditing Standards No. 61, , as amended (AICPA, Professional Standards, Vol. 1, AU section 380), as adopted by the Public Company Accounting Oversight Board (“PCAOB”) in Rule 3200T.  In addition, the Audit Committee received the written disclosures and the letter from the independent registered public accounting firm required by Rule 3526 of the PCAOB requiring independent registered public accounting firms to annually disclose in writing all relationships that, in their professional opinion may reasonably be thought to bear on independence, to confirm their perceived independence and to engage in a discussion of independence, and it has discussed with PricewatershouseCoopers AccountsKPMG Accountants N.V. its independence from the Company.

Based on the reviews and discussions described above, the Audit Committee recommended to the Board the inclusion of the audited financial statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017,2019, for filing with the Securities and Exchange Commission.

AGENDA ITEM XIIX

VOTING PROPOSAL NO. 10—REAPPOINTMENT10 - APPOINTMENT OF INDEPENDENT REGISTERED

PUBLIC ACCOUNTING FIRMKPMG ACCOUNTANTS N.V. AS EXTERNAL AUDITORS OF THE COMPANY FOR THE FINANCIAL YEAR 2020

The Board has selected PricewaterhouseCoopersKPMG Accountants N.V. (“PWC”KPMG”) to serve as our auditor and independent registered public accounting firm who will (i) audit the Dutch Annual Accountsstatutory annual accounts to be prepared in accordance with the International Financial Reporting Standards, as adopted by the European Union (IFRS)(“IFRS”), for the year ending December 31, 20182020 and (ii) serve as our independent registered public accounting firm for purposes of reporting pursuant to U.S. law for the fiscal year ending December 31, 2018.2020.  As required by Dutch law, shareholder approval must be obtained for the selection of PWCKPMG to serve as our auditor and independent registered public accounting firm.

KPMG has served as our independent registered public accounting firm since June 2019. The services provided to us by KPMG as well as the predecessor auditor PricewaterhouseCoopers Accountants N.V. (“PWC”) during the years ended December 31, 2019 and 2018 are described below under “Principal Accountant Fee Information.”  We expect that a representativerepresentatives of PWCKPMG will be present at the 2020 Annual Meeting and will be available to answer appropriate questions. The representativerepresentatives will also have the opportunity to make a statement if they desire to do so.

PWC has servedwas dismissed as our independent registered public accounting firm sinceof April 2013.  The services provided to us by PWC during25, 2019.  KPMG’s report on the yearsfinancial statements for the fiscal year ended December 31, 20172019, which is the only such report issued for these financial statements, does not contain an adverse opinion or a disclaimer of opinion, and 2016 are described below under “Principal Accountant Fee Information.”it was not qualified or modified as to uncertainty, audit scope, or accounting principles.

The Audit Committee annually reviews the independent registered public accounting firm’s independence, including reviewing all relationships between the independent registered public accounting firm and us and any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, and the independent registered public accounting firm’s performance. We do not believe that any relationships exist which would interfere with PwC’s or KPMG’s independence.

Required Disclosures

As reported on our Current Report on Form 8-K filed with the SEC on April 29, 2019:

On April 25, 2019, the Audit Committee dismissed PWC as our auditor and independent registered public accounting firm, which was effective upon completion of the first quarter 2019 review procedures.

PWC’s reports on our consolidated financial statements for the years ended December 31, 2019 and 2018 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

During our fiscal year ended December 31,2018, and the subsequent interim period through April 25, 2019, there were (i) no disagreements, within the meaning of Item 304(a)(1)(iv) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended (“Regulation S-K”), and the related instructions thereto, with PWC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of PWC, would have caused it to make reference to the subject matter of the disagreements in connection with its reports on our consolidated financial statements for such years, and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K and the related instructions thereto.

Principal Accountant Fees and Services

We regularly review the services and fees of our independent registered public accountants.accounting firms.  These services and fees are also reviewed by the Audit Committee on an annual basis.  The following table shows the fees paid or accrued by the Company for audit and other services provided by PWCKPMG for the fiscal yearsyear ended December 31, 20172019 and 2016:by PwC for the fiscal year ended December 31, 2018:

(1)         Audit-related fees for the year ended December 31, 2019 consisted of the aggregate fees accrued for assurance services rendered by KPMG of $ 117 thousand and PwC of $131 thousand related to equity offerings.

(2)         Audit-related fees for the year ended December 31, 2018 consisted of the aggregate fees accrued for assurance services rendered by PwC related to equity offerings.

We accrued no fees to KPMG for audit services for the fiscal year ended December 31, 2018.

Pre-Approval Policies and Procedures

The Audit Committee pre-approves all auditing services, internal control related services and permitted non-audit services (including the fees and terms thereof) to be performed, by PWC, subject to the de minimis exception for non-audit services that are approved by the Audit Committee prior to the completion of an audit.  The Audit Committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by the Company’s independent registered public accounting firm. This policy generally provides that the Company will not engage its independent registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by the Audit Committee or the engagement is entered into pursuant to the pre-approval procedure described below.

From time to time, the Audit Committee may pre-approve specified types of services that are expected to be provided to the Company by its independent registered public accounting firm during the next 12 months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.

The Audit Committee pre-approved all services performed since the pre-approval policy was adopted.

VOTE REQUIRED

The affirmative vote of a majority of our Ordinary Shares present in person or represented by proxy at the 20182020 Annual Meeting and entitled to vote, is required to approve Voting Proposal No. 10. Brokers will have discretion to vote on this item.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE APPOINTMENT OF PRICEWATERHOUSECOOPERSKPMG ACCOUNTANTS N.V.  AS THE COMPANY’S EXTERNAL AUDITORS AND INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2018.2020.

AGENDA ITEM XIII—XI

VOTING PROPOSAL NO. 11 — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS OF THE COMPANY

As required by Section 14A of the Exchange Act, the Company’s shareholders have the opportunity to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in this Proxy Statement in accordance with the SEC rules, which we also have referred to herein as the Say-on-Pay vote.

Our executive compensation program is designed to align compensation metrics with our strategic imperatives, align the interests of management with our shareholders, and attract and retain talented executives. Please see the Compensation Discussion and Analysis beginning on page [  ] of this Proxy Statement for additional details, including information about the fiscal year 2019 compensation of our named executive officers.

We believe that Shareholders have benefitted from the continued development of our product candidates and research pipeline over the past year. Given the Company’s development and growth under the leadership of the named executive officers, the Board recommends that shareholders vote “FOR” the following resolution at our 2020 Annual Meeting:

“RESOLVED, that the Company’s shareholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed on pages [  ] to [  ] of the Proxy Statement for the 2020 Annual Meeting pursuant to Item 402 of Regulation S-K, including the Compensation Discussion and Analysis, the 2019 Summary Compensation Table, and the other related tables and disclosure.”

It is expected that the next say-on-pay vote will occur at our 2021 annual general meeting of shareholders.

VOTE REQUIRED

Although advisory and not binding, the Compensation Committee and the Board will take into account the outcome of this vote on Voting Proposal No. 11 when considering future compensation arrangements for the Company’s named executive officers.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE OFFICERS, AS STATED IN THE ABOVE RESOLUTION.

AGENDA ITEM XII - ANY OTHER BUSINESS

The 20182020 Annual Meeting will review and discuss any other business brought to its attention.

AGENDA ITEM XIV—XIII - CLOSING OF THE MEETING

The Chairman will adjourn the meeting.

CORPORATE GOVERNANCE

Board of Directors (the “Board”) Leadership Structure and Composition

We have a one-tier board structure under Dutch law.law, meaning that executive and non-executive directors are members of the same board of directors.  Our Articles of Association provide that the number of members of our Board will be determined by our Board, provided that the Board shall be comprised of at least one executive director and at least twoone non-executive director and provided further that the number of executive directors shall at all times be less than the number of non-executive directors.  Our Board currently consists of sevennine directors, onetwo of whom is anare executive directordirectors and sixseven of whom are non-executive directors. If a director is to be appointed, the non-executive directors make a binding nomination, which is approved by the general meeting of shareholders pursuant to the procedure described in voting proposals number 3 and 4.Voting Proposal Numbers 3-6. Under our Articles of Association, a general meeting of shareholders may suspend or dismiss a director by at least a two thirdstwo-thirds majority of votes cast, provided that such majority represents more than half of the issued share capital. The Board may suspend (but may not dismiss) an executive director. In the event of an absence or inability to act with respect to one or more of the directors, our Articles of Association provide that the non-executive directors shall be authorized to temporarily fill the vacant position for a period up to the first general meeting, or in the case of a director unable to act, up to the moment he is no longer ableunable to act.

Under our Articles of Association and Dutch law, the members of our Board are collectively responsible for our management, general and financial affairs, and policy and strategy.  Our executive director isdirectors are primarily responsible for managing our day-to-day affairs.  Our non-executive membersdirectors supervise our executive directordirectors and our general affairs, and provide general advice to him.them.  In performing their duties, our directors are guided by the interest of our Company and, with the boundaries set by relevant Dutch law, must take into account the relevant interests of our stakeholders.  In consultation with the Nominating and Corporate Governance Committee, the Board has determined that the current board structure is appropriate for the Company. Having staggered, multiple-year terms for each of our directors provides for stability, continuity and experience among our Board. Further, the Board believes that building a cohesive board of directors is an important goal. In our industry in particular, long-term focus is critical. The time horizon required for successful development of gene therapies makes it vital that we have a board that understands the implications of this process and has the ability to develop and implement long-term strategies while benefiting from an in-depth knowledge of our business and operations. Our current board structure helps to ensure that there will be the continuity and stability of leadership required to resist the pressure to focus on short-term results at the expense of the long-term value and success of the Company. Our future success depends in significant part on the ability to attract and retain capable and experienced directors. In this regard, we believe that longer terms for our directors will enhance director independence from both management and stockholder special interest groups.

Under our Articles of Association and consistent with Dutch corporate governance principles, the Board appoints an executive director as chief executive officerChief Executive Officer and appoints a non-executive director as chairmanChairman of the Board. We believe that the separation of these roles servicesserves our shareholdersShareholders and us well. Philip Astley-Sparke serves as our Chairman.  The duties and responsibilities of the Chairman include, among others: determining the agenda and chairing the meetings of the Board, managingmonitoring our Board to ensure that it operates effectively, ensuring that the members of our Boarddirectors receive accurate, timely, and clear information, encouraging active engagement by all members of our Board,directors, promoting effective relationships and open communication between the non-executive directors and the executive directors, and monitoring effective implementation of our Board decisions.

There are no arrangements or understandings between the directors or executive officerssenior management and any other person pursuant to which our directors or executive officerssenior management have been selected for their respective positions.

Directors and Senior Management

Set forth below are the names of our current directors and executive officers, their ages (as of March 31, 2018)2020), all positions and offices that they hold with us, the period during which they have served as such, and their business experience during at least the last five years.

MATTHEW KAPUSTA. Matthew Kapusta, age 45, joined47, has been Chief Executive Officer of uniQure since December 2016, and currently serves on the Company’s Board of Directors. Mr. Kapusta also has served as our Chief Financial Officer since joining uniQure in January 2015 and was elected to our Management Board at the 2015 annual general meeting. In December 2016 he was appointed our chief executive officer.2015. Prior to joining uniQure, Mr. Kapusta was Senior Vice President at AngioDynamics (NASDAQ: ANGO) from 2011 to 2014, responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance and Strategic Planning and Analysis for Smith & Nephew Orthopaedics. Mr. Kapusta’s career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Mr. Kapusta was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. Mr. Kapusta holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young. We believe that Mr. Kapusta is qualified to serve as our CEO, Executive Director and Principal Financial Officer due to his broad expertise in the biotechnology and finance industries.

ROBERT GUT, M.D., Ph.D. Dr. Robert Gut, age 55, joined uniQure as our Chief Medical Officer in August 2018 and was elected as an executive director to our Board at the October 2018 extraordinary general meeting.  Dr. Gut was originally elected to the Board as a non-executive director in June 2018 He resigned that position in August 2018 to take the position of Chief Medical Officer because under Dutch law our non-executive directors are not able to hold executive positions with the Company.  Dr. Gut has more than 20 years of experience in the biopharmaceutical industry leading clinical development and medical affairs activities in hematology and other therapeutic areas. For the majority of his career, Dr. Gut served as Vice President, Clinical Development & Medical Affairs at Novo Nordisk Inc. (NYSE: NVO), where he headed the company’s U.S. Biopharm Medical organization with leading products in hemophilia, endocrinology and women’s health (NovoSeven®, Norditropin® and Vagifem®), totaling approximately $1.6 billion in U.S. revenue. Over his career, Dr. Gut’s contributions have helped achieve six FDA product approvals and three new product indications. Dr. Gut has supported the launch of nine new products, overseeing medical activities including medical science liaison team building and health economics and outcomes research. He has also served as a member of the Advisory Committees for Reproductive Health Drugs and Drug Safety and Risk Management for the FDA’s Center for Drug Evaluation and Research. Dr. Gut was appointed the Chief Medical Officer of Versartis, Inc. in September 2017 and received his Doctor of Medicine degree from the Medical University of Lublin, and his Doctorate degree from Lublin Institute of Medicine, Poland. He attended numerous postgraduate programs at Wharton, Stanford and Harvard Business School.

PHILIP ASTLEY-SPARKE.  Philip Astley-Sparke, age 46,48, has served as a member of our Board since June 2015 and as chairman since 2016. He was previously president of uniQure Inc. from January 2013 until February 2015 and was responsible for building uniQure’s U.S. infrastructure. Mr. Astley-Sparke is currently Chief Executive ChairmanOfficer and co-founder of Replimune Limited,Group, Inc. (NASDAQ: REPL), a company developing second-generation oncolytic vaccines. Mr. Astley-Sparke served as Vice President and General Manager at Amgen, Inc. (NASDAQ: AMGEN), a biopharmaceutical company, until December 2011, following Amgen’s acquisition of BioVex Group, Inc., a biotechnology company, in March 2011. Mr. Astley-Sparke had been President and Chief Executive Officer of BioVex Group, which developed the first oncolytic vaccine to be approved in the western world following the approval of Imlygic in 2015. He oversaw the company’s relocation to the U.S. from the UK in 2005. Prior to BioVex, Mr. Astley-Sparke was a healthcare investment banker at Chase H&Q/Robert Fleming and qualified as a Chartered Accountant with Arthur Andersen in London. MrMr. Astley-Sparke has been a Venture Partner at Forbion Capital Partners, a venture capital fund, since May 2012 and serves as Chairman of the Board of Oxyrane, a biotechnology company. We believe that Mr. Astley-Sparke is qualified to serve as a Non-Executive Director due to his expertise and experience in the biotechnology industry.

MADHAVAN BALACHANDRAN. Mr. Balachandran, age 67,69, has served as a member of our Board since September 2017. Mr. Balachandran has been a director of Catalent (NYSE: CTLT) since May 2017.  Mr. Balachandran was Executive Vice President, Operations of Amgen Inc., a global biotechnology company, from August 2012 until July 2016 and retired as an Executive Vice President in January 2017. Mr. Balachandran joined Amgen in 1997 as Associate Director, Engineering. He became Director, Engineering in 1998, and, from 1999 to 2001, he held the position of Senior Director, Engineering and Operations Services before moving to the position of Vice President, Information Systems from 2001 to 2002. Thereafter, Mr. Balachandran was Vice President, Puerto Rico Operations from May 2002 to February 2007. From February 2007 to October 2007, Mr. Balachandran was Vice President, Site Operations, and from October 2007 to August 2012, he held the position of Senior Vice

President, Manufacturing. Prior to his tenure at Amgen, Mr. Balachandran held leadership positions at Copley Pharmaceuticals, now a part of Teva Pharmaceuticals Industries Ltd., and Burroughs WelcomeWellcome Company, a predecessor throughbefore mergers of GlaxoSmithKline plc. Mr. Balachandran holds a Master of Science degree in Chemical Engineering from The State University of New York at Buffalo and an MBA from East Carolina University. We believe Mr. Balachandran is qualified to serve as a Non-Executive Director due to his extensive experience in the biotechnology industry.

JACK KAYE. Jack Kaye, age 74,76, has served as a member of our Board since 2016. Mr. Kaye has also served as Chairman of the Audit Committee of Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) from 2006 to 2016 and is currently chairman of the Audit Committee and a member of the Compensation Committee of Dyadic International, Inc. (OTC: DYAI). Mr. Kaye began his career at Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006. At Deloitte, he was responsible for servicing a diverse client base of public and private, global and domestic companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley matters. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than 20 years. Mr. Kaye has a Bachelor of Business Administration from Baruch College and is a Certified Public Accountant. We believe that Mr. Kaye is qualified to serve as a Non-Executive Director due to his extensive accounting and financial experience.

DAVID SCHAFFER.MEEK. David Meek, age 56, has 30 years of experience in the pharmaceutical industry, where he has held various global executive positions in major pharmaceutical and biotechnology companies. In January 2020, Mr. Meek was appointed President & CEO of FerGene, a gene therapy biotech focused on cancer.  From July 2016 to December 2020, Mr. Meek was CEO and a member of the Board of Ipsen.  Prior to joining Ipsen, he was Executive Vice-President and President of the oncology division of Baxalta. He spent 2 years as CCO of Endocyte.  Mr. Meek also spent 8 years at Novartis as a global franchise head, CEO of Novartis Canada, and region head of oncology for northern, central and Eastern Europe.  He also spent 14 years at Johnson & Johnson and Janssen Pharmaceutica, where he held a variety of senior U.S. sales and marketing positions. Mr. Meek holds a B.A. from the University of Cincinnati.

DAVID SCHAFFER, PH.D. David Schaffer, age 47,49, has served as a member of our Board since January 2014. Dr. Schaffer is Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at

University of California Berkeley, a position he has held since 2007, as well as Director of the Berkeley Stem Cell Center since 2011. Dr. Schaffer is also co-founder and the current Chief Scientific Officer of 4D Molecular Therapeutics, a company specializing proprietary technology for gene therapy products. We entered into a collaboration and license agreement with 4D Molecular Therapeutics in January 2014. Previously, Dr. Schaffer was Assistant Professor from 1999 to 2005 and Associate Professor from 2005 to 2007 at the University of California, Berkeley Department of Chemical Engineering & Helen Wills Neuroscience Institute. He has served on the boards of the American Society for Gene and Cell Therapy and the Society for Biological Engineering. He has more than 25 years of experience in chemical and molecular engineering, and stem cell and gene therapy research, has over 185210 scientific publications, and serves on fivesix journal editorial boards and five industrial scientific advisory boards. Dr. Schaffer holds a bachelorBachelor of scienceScience degree in Chemical Engineering from Stanford University and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology. We believe that Dr. Schaffer is qualifiednot standing for reappointment to serve as a Non-Executive Director due to his experience in the biotechnology industry and his expertise in that field.Board for another term.

PAULA SOTEROPOULOS.Paula Soteropoulos, age 50,52, has served as a member of our Board since July 2013. Ms. Soteropoulos is an executive leader with more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization and company building. Since March 2020, she serves as Strategic Advisor to 5AM Ventures and is Executive Chairman of a 5AM Venture NewCo.  From January 2015 through September 2019, she served as President and Chief Executive Officer of Akcea Therapeutics a position she has held since January 2015.(NASDAQ: AKCA). From July 2013 to December 2014, she served as Senior Vice President and General Manager, Cardiometabolic Business and Strategic Alliances at Moderna Therapeutics Inc. Prior to this, Ms. Soteropoulos worked at Genzyme Corporation, a biotechnology company, from 1992 to 2013, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Ms. Soteropoulos holds a bachelorBachelor of scienceScience degree in chemical engineering and a masterMaster of scienceScience degree in chemical and biochemical engineering, both from Tufts University, and holds an executive management certificate from the University of Virginia, Darden Graduate School of Business Administration. Ms. Soteropoulos serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University. We believe Ms. Soteropoulos is qualified to serve as a Non-Executive Director due to her extensive experience in the biotechnology industry.

JEREMY P. SPRINGHORN, PH.D. Dr. Springhorn, age 55,57, has served as a member of our Board since September 2017. FromSince November 2017, Dr. Springhorn has been Chief Business Officer of Syros Pharmaceuticals (NASDAG:(NASDAQ: SYRS), Inc..Inc. Prior to taking his position at Syros, Dr. Springhorn most recently served as Partner, Corporate Development at Flagship Pioneering from March 2015 until June 2017 where he worked with VentureLabs (inin helping companies in various strategic and corporate development capacities and in creating next generation startups)startups and with Flagship’s Corporate Limited Partners. Prior to joining Flagship, Dr. Springhorn was one of the original scientists at Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), where he played an integral role in its antibody engineering capabilities and was one of the original inventors of the drug Soliris.Soliris®. At Alexion Pharmaceuticals, Dr. Springhorn was Vice President of Corporate Strategy and Business Development from 20092006 until March 2015 and Head of

Global2015. Dr. Springhorn started at Alexion in 1992 where he served in various leadership roles in R&D before switching to Business Development and Corporate Strategy from December 2006 until 2009. In 2006, Dr. Springhorn moved from research to business development, leveraging much of his drug development experience into the review of opportunities for ultra-orphan diseases. Dr. Springhorn also served as Head of Corporate Strategy as Alexion transitioned from a development firm to a global commercial stage company.in 2006. Prior to 1992, Dr. Springhorn received his Ph.D. from Louisiana State University Medical Center in New Orleans and did his postdoctoral training at the Brigham and Woman’s Hospital in Boston.  DrBA from Colby College. Dr. Springhorn currently serves on the Board of OverseersDirectors for Colby College andNMD Pharma, Board of Advisors for Mythic Therapeutics.Therapeutics and the Board of Visitors for Colby College. We believe Dr. Springhorn is qualified to serve as a Non-Executive Director due to his extensive experience in the biotechnology industry.

DR. ALEXANDER KUTA, PH.D. Dr. Kuta, age 60, has served as our Senior Vice President Regulatory Affairs since January 2017.  Prior to joining uniQure, he was Vice President of Research & Development Global Regulatory Affairs for EMD Serono, responsible for immune-mediated diseases, oncology and biologics regulatory CMC, from January 2016 to September 2016.  He joined EMD Serono in April 2013 as Vice President, Head of US Regulatory Affairs; while at EMD Serono he served on the US Leadership Team.  From April 2012 to March 2013, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging. His previous industry experience includes senior regulatory leadership roles at AMAG Pharmaceuticals (NASDAQ: AMAG) from August 2010 to April 2012 as well as Genzyme Corporation from August 1995 to July 2010 where he worked in the areas of rare diseases, cell and gene therapy, therapeutic proteins and biomaterials.  Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA from January 1993 to August 1995 and a Scientific Reviewer from January 1990 to January 1993.  Dr. Kuta has served on the BIO Regulatory Affairs Leadership Committee - Cell and Gene Therapy Working Group, as reviewer for the National Gene Vector Laboratories program, on the ICH (M6) Gene Therapy Working

Group and is currently on the scientific review board of the Gene Therapy Resource Program of NHLBI/NIH. Dr. Kuta holds a Bachelor of Science degree from Saint John’s University, Collegeville, MN and a Ph.D. from the Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/National Institutes of Health.

SANDER VAN DEVENTER.DEVENTER, M.D., Ph.D. Dr. Sander van Deventer, age 63, has served65, is one of our co-founders and currently serves as our Chief Scientific OfficerExecutive Vice President, Program and General Manager, Amsterdam since August 2017.  He previouslyResearch Development.  Prior to rejoining the Company in 2017, he served as a member of our Board from April 2012 until September 2017 and served as member of the AMT supervisory board from April 2010 to April 2012. Dr. van Deventer was one of our co-founders. He served as our interim Chief Executive Officer from February to October 2009. He has been Professor of Translational Gastroenterology at the Leiden University Medical Center since 2008 and is a partner of Forbion Capital Partners, which he joinedco-founded in 2006. He serves on the boardsboard of enGene Inc., Argos Biotherapeutics, gICare Pharma Inc and Hookipa Biotech. He was previously a professor, head of the department of experimental medicine and chairman of the department of gastroenterology of the Academic Medical Center at the University of Amsterdam from 2002 to 2004, and subsequently professor of experimental medicine at the University of Amsterdam Medical School until 2008. Dr. van Deventer is currently a professor at Leiden University Medical Center. He has more than 1520 years of experience in biotechnology product development. He is the author of more than 400 scientific articles in peer-reviewed journals, and he serves as an advisor to regulatory authorities including the EMA and FDA. Dr. van Deventer holds a degree in medicine as well as a Ph.D. from the University of Amsterdam.

ALEXANDER KUTA, PH.D.. Dr. Kuta, age 58, has served as our Senior Vice President Regulatory Affairs since January 2017. Dr. Kuta joined uniQure from EMD Serono where he served as Vice President of Research & Development Global Regulatory Affairs from 2016 to 2017 and was a member of the U.S. Leadership Team.  In this role, he was responsible for driving the strategic direction of EMD Serono’s regulatory efforts in immune-mediated diseases, oncology and regulatory CMC, as well as strengthening interactions with the U.S. Food and Drug Administration (FDA). He joined EMD Serono in 2013 as Vice President, US Regulatory Affairs and member of the US Leadership Team. Prior to EMD Serono, Dr. Kuta was Vice President of Global Regulatory Affairs and a member of the Executive Leadership Team at Lantheus Medical Imaging from 2012 to 2013. His previous experience includes senior roles at AMAG Pharmaceuticals (NASDAQ: AMAG) and at Genzyme Corporation, where he served for 15 years in regulatory leadership positions of increasing responsibility.  Prior to joining industry, he was Chief of the Cytokine and Gene Therapy Branch in the Center for Biologics at FDA.   Dr. Kuta has also served as a member of the BIO Regulatory Affairs Leadership Committee, Cell and Gene Therapy Working Group and the ICH Gene Therapy Working Group. Dr. Kuta holds a Bachelor of Science degree from Saint John’s University and a Ph.D. from Chicago Medical School at Rosalind Franklin U-Med & Science. He conducted his post-doctoral studies at the National Cancer Institute/ National Institutes of Health.

CHRISTIAN KLEMT. Christian Klemt, age 45, has served as our Chief Accounting Officer since August 2017. From September 2015 until August 2017, Mr. Klemt served as our Global Controller. While serving as our Global Controller, Mr. Klemt oversaw our transition to a domestic U.S. filer and conversion to U.S. Generally Accepted Accounting Principles. Mr. Klemt jointed us from CGG SA (NYSE: CGG) where he held the position of Regional Finance Director and Country Manager. Prior to this, he held various senior finance roles including Group Finance Manager at Basell Polyolefines N.V. (now LyondellBasell N.V.) (NYSE: LBI) where he led the conversion to U.S. Generally Accepted Accounting Principles following the acquisition of Lyondell and was involved in the acquisition of various petrochemical assets. Mr. Klemt holds a Master’s degree in Business Administration from the University of Muenster, Germany and qualified as a German Certified Public Accountant and Tax Advisor while employed at KPMG.

SCOTT MCMILLAN, PH.D. Dr. McMillan, age 59, has served as our Chief Operating Officer since August 2017. Dr. McMillan served most recently as Senior Vice President of Quality and Technical Operations at AMAG Pharmaceuticals from February 2008 to August 2017, where he also was a member of its Executive Management Team. Before joining AMAG Pharmaceuticals, from January 2005 to February 2008 Dr. McMillan held similar positions at AVANT Immunotherapeutics, Inc., and from January 2002 to January 2005 with Johnson Matthey

Pharmaceutical Materials, Inc. Dr. McMillan has over 25 years of biotechnology experience in quality, process development, scale-up, technology transfer from bench to commercial scale as well as manufacturing operations. Dr. McMillan holds a Ph.D. in Chemical Engineering from Georgia Institute of Technology, a Master’s degree in Economics and Bachelor’s degree in Chemical Engineering from the University of Delaware.

DR. STEVEN ZELENKOFSKE. Dr. Zelenkofske, age 59, has served as our Chief Medical Officer since June 2017. Dr. Zelenkofske has nearly 15 years of clinical research experience within the industry, having previously held leadership positions at AstraZeneca, Sanofi-Aventis, Boston Scientific, and Novartis Pharmaceuticals. Most recently, from November 2014 to May 2017 he served as Vice President and Therapeutic Area Head of Cardiovascular/Metabolism for AstraZeneca. Prior to joining AstraZeneca, he served as Chief Medical Officer for Regado Biosciences, a developer of RNA aptamer therapies from January 2009 to November 2017. His clinical experience outside of industry includes serving on the cardiology and electrophysiology teams with Lehigh Valley Heart Specialists, Heart Care Group and Cardiology Care Specialists, all in Allentown, PA, and on the medical staff of Episcopal Hospital in Philadelphia. He holds Bachelor of Science and Master of Science degrees from Emory University and a Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine. He conducted his graduate medical education at the Philadelphia College of Osteopathic Medicine and is board-certified in internal medicine, cardiology and cardiac electrophysiology.

Risk Oversight

Generally, the Board, in its advisory capacity, and the Company’s management regularly review the Company’s strategic plan which includes, among other things, the various business, clinical, developmental, financial and other market risks confronting, and opportunities available to, the Company at any given time. Specifically, pursuant to the Company’s Corporate Governance Guidelines and Board Rules, the Board is charged with assessing major risks facing the Company and reviewing options to mitigate such risks. The Board performs this oversight role by using several different levels of review. In connection with its reviews of the operations and corporate functions of the Company, the Board addresses the primary risks associated with those operations and corporate functions. In addition, the Board reviews the risks associated with the Company’s business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies.

The Board has delegated certain risk oversight responsibilities to its committees (the “Committees”). Each of our Board’s Committees also oversees the management of the Company’s risk that falls within each Committee’s areas of responsibility. In performing this function, each Committee has full access to management, as well as the ability to engage advisors. For example, the Audit Committee is required to regularly review and discuss with management the Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures. The Nominating and Corporate Governance Committee is required to regularly review the corporate governance principles of the Company and recommend to the Board any proposed changes it may deem appropriate.  The Compensation Committee considers risks related to the attraction and retention of professional talent and the implementation and administration of compensation and benefit plans affecting the Company’s employees.  All Committees are required, pursuant to their respective charters, to report regularly to the Board.  The activities of the Audit, Nominating and Corporate Governance and Compensation Committees are more fully described below.

Board Determination of Director Independence

Our securities are listed on the NASDAQNasdaq Global Select Market (“NASDAQ”Nasdaq”) and we use the standards of “independence” prescribed by rules set forth by Nasdaq.  Under Nasdaq rules, a majority of a listed company’s board of directors must be comprised of independent directors.  In addition, Nasdaq rules require that, subject to specified exceptions, each member of a listed company’s audit committee and compensation committee be independent and, in the case of audit committees, satisfy additional independence criteria set forth in Rule 10A-3, under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”).Act. Under Nasdaq rules, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

Based upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our Board has determined that each of Philip-Astley Sparke, Madhavan Balachandran, Jack Kaye, David Meek, Paula Soteropoulos, and Jeremy Springhorn Madhavan Balachandran and Philip-Astley Sparke has no relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of the Nasdaq rules and the SEC.  Our Board has determined that each of Matthew Kapusta, Robert Gut and David Schaffer do not qualify as “independent” under the Nasdaq rules.  Our Board has also determined that each of the current members of our Audit Committee and our Compensation Committee satisfies the independence standards for such committee established by Rule 10A-3 under the Exchange Act, the SEC rules and the Nasdaq rules, as applicable, and that the current members of the Nominating and Corporate Governance Committee are also independent.  In making these determinations, the directors reviewed and discussed information provided by the directors and the Company with regard to each director’s business and personal activities as they may relate to the Company and the Company’s management.

Board Meetings

The Board met 911 times during the calendar year ended December 31, 2017.2019.  Each of theour directors attended at least 75% of the meetings of the Board and the Committees on which he or she served during the year ended December 31, 20172019 (in each case, which was held during the period for which he or she was a director and/or a member of the applicable Committee).  Dr. van Deventer, a director at the time, Mr. Kaye, Mr. Astley-Sparke, andMr. Balachandran, Dr. Gut, Mr. Kapusta, Mr. Meek, and Ms. Sotoropoulous attended our 2017 annual meeting2019 Annual General Meeting of shareholdersShareholders held on June 14, 2017.19, 2019.  The Company encourages its directors to attend the annual general meeting of Shareholders.shareholders. Executive sessions, or meetings of the independent directors without management present, are held regularly.

Committees and Committee Meetings

The Board has a standing Audit Committee, Nominating and Corporate Governance Committee, Compensation Committee, and CompensationResearch and Development Committee, each of which is comprised solely of independent directors, and is described more fully below. The members of each Committee are appointed by our Board.  From time to time, the Board may establish other committees.  Below is a description of the threefour principal Committees.Committees of our Board.

Audit Committee and Audit Committee Financial Expert

The Audit Committee is currently comprised of Jack Kaye, Philip Astley-Sparke and Jeremy Springhorn. Mr. Kaye serves as the Chair of the Audit Committee.  The Audit Committee has determined that Mr.  Kaye is independent within the meaning of the SEC and Nasdaq rules and is an “audit committee financial expert” within the meaning of the SEC’s rules and regulations and has the level of financial sophistication required by Nasdaq Rule 5605(c)(2)(A).  The Audit Committee believes that Mr. Kaye’s experience, as discussed in his biography above, qualifies him as an “audit committee financial expert.”  Each of Mr. Kaye, Mr. Astley-Sparke and Dr. Springhorn satisfies the director independence standards and the independence standards for members of the Audit Committee established by SEC and Nasdaq.

As noted above, the Audit Committee is governed by the Audit Committee Charter.  A copy of this Charter is available on our website at www.uniqure.com under “Investors & Newsroom — Corporate Governance — uniQure Audit Committee Charter.”  In addition to the risk oversight responsibilities discussed above, the Audit Committee’s other responsibilities include recommending the selection of our independent registered public accounting firm; reviewing with the Company’s independent registered public accounting firm the procedures for and results of their audits; reviewing with the independent accountants and management our financial reporting,  internal controls and internal audit procedures; reviewing and approving related party transactions; and reviewing matters relating to the relationship between the Company and our independent registered public accounting firm, including the selection of and engagement fee for our independent registered public accounting firm, and assessing the independence of the independent registered public accounting firm.  The Audit Committee has the authority to engage independent legal, accounting and other advisers, as it determines necessary to carry out its duties.

The Audit Committee met 75 times during 2017.2019.

Compensation Committee

The Compensation Committee is currently comprised of Madhavan Balachandran, Jack Kaye Madhavanand David Meek.  Mr. Balachandran and Paula Soteropoulos.  Mr. Kaye serves as the Chair of the Compensation Committee. Following the Annual Meeting, the Board intends to appoint Dr. Gut to serve on the Compensation Committee, and expects that Ms. Soteropoulos will resign from the Compensation Committee and that Mr. Balachandran will serve as the Chair.  Each of Mr. Balachandran, Mr. Kaye, and Mr. Balachandran, Ms. Soteropoulos and. Dr. GutMeek satisfies the director independence standards and the independence standards for members of the Compensation Committee established by the SEC and Nasdaq. The Compensation Committee is governed by the Compensation Committee Charter. A copy of this Charter is available on our website at www.uniqure.com under “Investors & Newsroom — Corporate Governance —  uniQure Compensation Committee Charter.” In addition to the risk oversight responsibilities discussed above, the Compensation Committee’s other responsibilities include reviewing and approving or recommending to the Board for approval, as appropriate, the compensation of our executive officers following consideration of corporate goals and objectives relevant to such executive officers; overseeing the evaluation of the Company’s senior executives; reviewing and making recommendations to the Board regarding incentive compensation and equity-based plans; and administering our stock option plans.

Without further action from the Board, the Compensation Committee has the authority to retain compensation consultants and other outside advisors to assist in the evaluation of executive officer compensation and is empowered to pay compensation to such consultants and other outside advisors.

The Compensation Committee retained Willis Towers Watson to act as a compensation consultant during the year ended December 31, 2017. The compensation consultant provided assistance2019 to assist in designing and reviewing our management and director compensation programs. Willis Towers Watson’s engagement included reviewing base salaries, equity incentivesFor further information, please refer to “Compensation Discussion and other compensation for directors and senior management, including against a peer group of companies. In making decisions regarding the form and amount of compensation to be paid to directors and senior management, the Compensation Committee considered the information gathered by and recommendations of Willis Towers Watson. The Compensation Committee has assessed the independence of Willis Towers Watson pursuant to SEC rules and Nasdaq listing rules and concluded that the work of Willis Towers Watson did not raise any conflicts of interest.Analysis,” below.

The Compensation Committee met 710 times during 2017.2019.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is currently comprised of Jeremy Springhorn, Philip Astley-Sparke and Paula Soteropoulos.  Following the Annual Meeting, the Board intends to appoint Mr. Astley-Sparke to serve on the Nominating and Corporate Governance Committee.  Dr. Springhorn currently serves as the Chair of the Nominating and Corporate Governance Committee. Each of Dr. Springhorn, Ms. Soteropoulos and Mr. Astley-Sparke satisfy the independence standards established by SEC and Nasdaq. The Nominating and Corporate Governance Committee is governed by the Nominating and Corporate Governance Committee Charter. A copy of this Charter is available on our website at www.uniqure.com under “Investors & Newsroom—Newsroom — Corporate Governance — uniQure Nominating and Corporate Governance Committee Charter.”  In addition to the risk oversight responsibilities discussed above, the Nominating and Corporate Governance Committee’s other responsibilities include identifying individuals qualified to become Board members and to recommend to the Board the nominees for director at annual general meetings of Shareholders;shareholders; recommending to the Board nominees for each Committee; developing and recommending to the Board corporate governance principles applicable to the Company; and leading the Board in its annual review of the Board’s performance.

The Nominating and Corporate Governance Committee met 57 times during 2017.2019.

Research and Development Committee

The Research and Development Committee is currently comprised of Jeremy Springhorn, Philip Astley-Sparke and Paula Soteropoulos.  Dr. Springhorn currently serves as the interim Chair of the Research and Development Committee. Each of Dr. Springhorn, Ms. Soteropoulos and Mr. Astley-Sparke satisfy the independence standards established by SEC and Nasdaq. The Research and Development Committee is governed by the Research and Development Committee Charter. A copy of this Charter is available on our website at www.uniqure.com under “Investors & Newsroom — Corporate Governance — uniQure Research and Development Committee Charter.”  In addition to the risk oversight responsibilities discussed above, the Research and Development Committee’s other responsibilities include: serving as an advisory body to the Board in matters related to the Company’s technology, research and development activities, product pipeline, and manufacturing platform (the “Company’s Technology”); advising the Board on the strategic direction of the Company with respect to the Company’s Technology; and evaluating the function and effectiveness of the Company’s research, development, manufacturing operations, clinical operations, and other technical, scientific and medical operations.

The Research and Development Committee was formed in December 2019 and did not meet in 2019.

Polices Governing Director Nominations

Director Nomination Process

Our Board is responsible for selecting its own members.members for appointment. The Board delegates the selection and nomination process to the Nominating and Corporate Governance Committee, with the expectation that other members of the Board, and of management, will be requested to take part in the process as appropriate. The Nominating and Corporate

Governance Committee makes recommendations to the Board regarding the size and composition of the Board. The Nominating and Corporate Governance Committee is responsible for ensuring that the composition of the Board accurately reflects the needs of the Company’s business and, in furtherance of this goal, for proposing the addition of members and the necessary resignation of members for purposes of obtaining the appropriate members and skills. The Nominating and Corporate Governance Committee recommends, and the Board nominates,non-executive directors nominate, candidates to stand for electionappointment as directors.

Generally, our Nominating and Corporate Governance Committee identifies candidates for director nominees in consultation with management, through the use of other advisors, through the recommendations submitted by shareholders or through such other methods as the Nominating and Corporate Governance Committee deems to be helpful to identify candidates. Candidates recommended by shareholders and other stakeholders are given appropriate consideration in the same manner as other candidates. Once candidates have been identified, our Nominating and Corporate Governance Committee confirms that the candidates meet all of the minimum qualifications for director nominees established by the Nominating and Corporate Governance Committee. The Nominating and Corporate Governance Committee may gather information about the candidates through interviews, detailed questionnaires, background checks or any other means that the Nominating and Corporate Governance Committee deems to be appropriate in the evaluation process. The Nominating and Corporate Governance Committee then meets as a group to discuss and evaluate the qualifications and skills of each candidate, both on an individual basis and taking into account the overall composition and needs of the Board. Based on the results of the evaluation process, the Nominating and Corporate Governance Committee recommends candidates as director nominees for electionappointment to the Board for the Board’s approval.

Qualifications

The Nominating and Corporate Governance Committee may receive from shareholders and others recommendations for nominees for electionappointment to the Board and recommend to the Board candidates for Board membership for consideration by the shareholders at the annual general meeting of Shareholders.shareholders. In recommending candidates to the Board, the Nominating and Corporate Governance Committee takes into consideration the Board’s criteria for selecting new directors, including, but not limited to, integrity, past achievements, judgment, intelligence, relevant experience and a commitment to understanding the Company’s business and its industry and the ability of the candidate to devote adequate time to Board duties. The Nominating and Corporate Governance Committee does not assign specific weights to particular criteria, and no particular criterion is a prerequisite for any Board candidate. We do however consider diversity in reviewing director candidates and do not discriminate on the basis of race, religion, sexual orientation, sex or national origin. Under Dutch law, as a company with fewer than 30% of the directors being women, we are required to disclose the rationale behind our failure to have a specified diversity percentage for the Board and our efforts to obtain such diversity. In order for the Board to fulfill its responsibilities, our Nominating and Corporate Governance Committee believes that the Board should include directors possessing a blend of experience, knowledge and ability, regardless of other characteristics.

Family Relationships

There are no family relationships among any of our directors or executive officers.

CompensationAny Shareholder wishing to recommend a candidate for Board membership should submit the recommendation in writing to Investor Relations at uniQure N.V., Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands. The written submission should set forth the candidate’s qualifications as specified in the uniQure Nominating and Corporate Governance Committee InterlocksCharter. The Nominating and Insider Participation

None of our executive officers currently serve, or have served duringCorporate Governance Committee will consider all candidates recommended by Shareholders who satisfy the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more executive officers serving as aminimum qualifications for director nominees and Board member of our Board or Compensation Committee.attributes.

Code of Business Conduct and Ethics and Corporate Governance Guidelines and Board Rules

We have adopted a code of business conduct and ethics that is applicable to all of our employees, officers, and directors, including our chief executive officerChief Executive Officer and chief financial officer.Chief Financial Officer.  The code of business conduct and ethics and corporate governance guidelines and board rules areis available on our website at www.uniqure.com. under “Investors & Newsroom — Corporate Governance —

uniQure Code of Business Conduct and Ethics.”  We have also adopted corporate governance guidelines and board rules which are applicable to the company’s management.management and are available on our website at www.uniqure.com under “Investors & Newsroom — Corporate Governance — uniQure Corporate Governance Guidelines and Rules for the Board of Directors”.

In addition to the Listing Rules of the NASDAQNasdaq Global Select Stock Market and rules and regulations as promulgated by the SEC, as a Dutch company, our governance practices are governed by the Dutch Corporate Governance Code.  The Dutch Corporate Governance Code (as amended) contains a number of principles and best practices, with an emphasis on integrity, transparency, and accountability as the primary means of achieving good governance.

There is considerable overlap between the requirements we must meet under U.S. rules and regulations and the provisions of the Dutch Corporate Governance Code.  Although we apply several provisions of the Dutch Corporate Governance Code, as a “domestic” issuer, we comply with the Nasdaq corporate governance requirements.

In accordance with the Dutch Corporate Governance Code’s compliance principle of “apply-or-explain,” which permits Dutch companies to be fully compliant with the Dutch Corporate Governance Code by either applying the Dutch practices or explaining why the company has chosen to apply different practices, we disclose in our Dutch statutory annual report that accompanies our Dutch statutory annual accounts to what extent we do not apply provisions of the Dutch Corporate Governance Code, together with the reasons for those deviations.  Our Dutch statutory annual report may be found on the “Investors & Newsroom — Events and Presentations” section of our website at http://www.uniqure.com/investors-newsroom/events-presentations.php.

DELINQUENT SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE16(A) REPORTS

Section 16(a) of the Exchange Act requires our executive officers, directors and persons who beneficially own more than ten percent of our Ordinary Shares to file reports of their beneficial ownership and changes in ownership (Forms 3, 4 and 5, and any amendment thereto) with the SEC. Executive officers, directors, and greater-than-ten-percent holders are required to furnish us with copies of all Section 16(a) forms they file. We were a foreign private issuer until January 1, 2017 and therefore our executive officers, directors and persons who beneficially own more than ten percent of our Ordinary Shares were not required to file reports of their beneficial ownership or changes in beneficial ownership prior to January 1, 2017.

Based solely upon a review of the Forms 3, 4, and 5, as applicable, furnished to us since we ceased to be a foreign private issuer on January 1, 2017, we have determinedbelieve that our executive officers, directors, and greater-than-ten-percent beneficial owners filed their beneficial ownership and change in ownership reports with the SEC in a timely manner during the 2019 calendar year, except as listed below.below:

CERTAIN RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS

Pre-Approval Policy Regarding Related Party Transactions

The Board has adopted a related party transactions policy, pursuant to which the Chief Financial Officer and the Audit Committee isare charged with reviewing and approving or disapproving related party transactions.  A “Related Party Transaction” under the policy means any transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) where the amount involved or proposed to be involved exceeds $120,000 (or its equivalent in any currency), in which the Company or any of its controlled subsidiaries was, is or will be a participant (i.e., not necessarily a party) and in which any Related Party, as defined below, had, has or will have a direct or indirect material interestinterest. The “Related Party Transactions Policy” supplements the provisions in the Company’s Code of Business Conduct and Ethics concerning potential conflict of interest situations. Pursuant to the policy, compensation of directors and senior management are reviewed and approved by the Compensation Committee.

This written policy covers transactions or series of transactions in which the Company or any subsidiary participates and a “Related Party” has or will have a direct or indirect material interest. For purposes of this policy, a “Related Party” is:

·                  Each director and executive officer of the Company and any person who was serving as a director and/or executive officer at any time since the beginning of the Company’s last fiscal year;

·                  Any nominee for electionappointment as a director of the Company;

·                  Any security holder who atis the timebeneficial owner or record holder of the occurrence of the transaction, owned beneficially or of record more than 5% of any class of the Company’s voting securities;

·                  Any immediate family member of any of the foregoing persons. An “immediate family member” includes the spouse, parents, stepparents, children, stepchildren, siblings, mothers- and fathers-in-law, sons- and daughters-in-law, brothers- and sisters-in-law, and any person (other than a tenant or employee) sharing the household of a director, executive officer, director nominee or greater than 5% security holder of the Company; and

·                  Any entity that employs any person identified in the above or in which any person identified in the above directly or indirectly owns or has a material interest.

Pursuant to the Related Party Transactions Policy, each Company executive officer, director or nominee for director or any other officer or employee who intends to cause the Company to enter into a related party transaction must fully disclose to the chief financial officerChief Financial Officer all material facts concerning a prospective transaction or arrangement involving the Company in which such person may have an interest. The Chief Financial Officer will review the information and make a preliminary, written conclusion as to whether the transaction is a related party transaction.  If the preliminary conclusion is that the transaction would be a related party transaction, the chief financial officerChief Financial Officer will present the information and his conclusion to the Audit Committee for review. If a member of the Audit Committee is involved in the transaction, that member will not participate in determining whether the related party transaction is approved or ratified by the Audit Committee. Annually, the Audit Committee will review any previously approved or ratified related party transactions that are continuing and determine based on then-existing facts and circumstances.

Before any related person transaction is approved, the following factors are to be considered:

·                  theThe Related Party’s interest in the transaction;

·                  theThe approximate value of the aggregate amount involved in the transaction;

·                  theThe approximate value of the amount of the Related Party’s interest in the transaction;

·                  aA summary of the material terms of and facts relating to the transaction, including any documentation or proposed documentation for the transaction, and identification of the area(s) of the Company’s business directly relevant to the transaction;

·                  whereWhere the transaction involves the purchase or sale of products, property or services, the availability of comparable products, property or services from or to (as applicable) unrelated third-party sources;

·                  whetherWhether the transaction was undertaken in the ordinary course of business of the Company;

·                  anAn assessment of whether the transaction’s terms are comparable to terms available from or to (as applicable) unrelated third parties in an arms-length transaction;

·                  theThe purpose of, and the potential benefits to the Company of the transaction; and

·                  anyAny other information regarding the transaction or the Related Party in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular transaction.

Approval of a transaction under the policy will be granted only if it is determined that, under all of the circumstances, the transaction is in, or not inconsistent with, the best interests of the Company.

Review of Related Party Transactions

Since January 1, 2017,2019, we have engaged in the following transactions with the members of our Board, senior management, parties that held more than 5% of our Ordinary Shares during that period, and their affiliates, which we refer to as our related parties. Each of these transactions was approved in accordance with our Related Transactions Policy.

Grants of Options to Related Parties

We grant options to members of the Board and senior management.  Details of options granted are included within the beneficial ownership table below.

4D Molecular Therapeutics Collaboration

In January 2014, we entered into a collaboration and license agreement with 4D Molecular Therapeutics.   4D Molecular Therapeutics, or 4DMT.  4DMT is a company co-founded by Dr. David Schaffer, whoand he currently serves as the Chief Scientific Officer. Dr. Schaffer was appointed to our Board in January 2014 pursuant to the terms of that collaboration.collaboration and license agreement.  In connection with this transaction, we agreed to provide specified research and development financing, areand were obligated to make certain upfront, royalty and milestone payments,payments. In August 2019, we entered into an amended and granted an option to Dr. Schaffer to purchase up to 609,744 Ordinary Shares at an exercise price of €0.05 per share. At October 1, 2014, 25% of the options vested (expiring at December 28, 2014), 50% of the options vested at January 31, 2015 (expiring on December 28, 2015) and the remainder vested on January 31, 2016 (expiring on December 28, 2016).  Therestated collaboration and license agreement expired(“Amended CLA”), as well as a separate new collaboration and license agreement (“New CLA”) with 4DMT. Pursuant to the terms of the Amended CLA, we received from 4DMT an exclusive sublicensable, worldwide license under certain 4DMT intellectual property rights to research, develop, make, use and commercialize previously selected AAV capsid variants and certain associated products using 4DMT proprietary AAV technology for delivery of gene therapy constructs to cells in the central nervous system and the liver (the “Field”). In accordance with its terms.the New CLA, the parties agreed to research and develop, at 4DMT’s cost, new AAV capsid variants using 4DMT proprietary AAV technology for delivery of up to

six additional transgene constructs in the Field that will be selected by us.  Dr. Schaffer is not standing for reappointment to the Board for another term.

BMS

In April 2015, we and Bristol Myers Squibb (“BMS”) entered into various commercial and investment agreements providing BMS exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular and other target-specific disease areas. We received $50 million in upfront payments upon effectiveness of the licensing and collaboration transaction in May 2015. An additional $15 million payment was received in July 2015 upon designation of three additional collaboration targets by BMS.  In addition, pursuant to the collaboration agreements, in June 2015, BMS purchased 1,112,319 of our Ordinary Shares for aggregate consideration of $37.6 million.  Immediately after the issuance, BMS owned 4.9% of our outstanding Ordinary Shares.  In August 2015, we issued an additional 1,275,789 of our Ordinary Shares to BMS for aggregate consideration of $37.9 million.  Immediately after the issuance, BMS owned 9.9% of our outstanding Ordinary Shares. We recognized $4.1$5.0 million in license revenue from BMS for the year ended December 31, 2017 (2016: $3.9 million.)2019 (2018: $7.5 million).

SECURITY OWNERSHIP OF CERTAIN

BENEFICIAL OWNERS AND MANAGEMENT(1)MANAGEMENT

Based on information publicly filed and provided to us by certain holders, the following table shows the number of our Ordinary Shares beneficially owned as of March 31, 2018,April 13, 2020 by (i) each person known by us to beneficially own more than five percent of our voting securities, (ii) each named executive officer, (iii) each of our directors, (iv) each of our director nominees, and (v) all of our current named executive officers and directors as a group.  Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.  In computing the number of shares beneficially owned by a person and the percentage ownership of that person, Ordinary Shares that could be issued upon the exercise of outstanding equity awards and warrants held by that person that are currently exercisable or exercisable within 60 days of March 31, 2018April 13, 2020 are considered outstanding.  As of March 31, 2018,April 13, 2020, we had 31,771,81644,299,596 Ordinary Shares outstanding. Unless otherwise stated in a footnote, each of the beneficial owners listed below has direct ownership of and sole voting power and investment power with respect to our Ordinary Shares.

Unless otherwise noted below, the address of each director and named executive officer is c/o uniQure N.V., Paasheuvelweg 25a, 1105BP1105 BP Amsterdam, the Netherlands.

* Denotes less than 0.01% beneficial ownership.

(1)              The registered office of Forbion 1, ForUniQure and Forbion Management is Gooimeer 2-35, 1411DC Naarden, The Netherlands. The number of shares reported is based solely on the Schedules 13G/A filed by ForUniQure B.V. and Forbion I Management B.V. on February 14, 2018 and Forbion I Co II Management B.V. on February 14, 2018 and with respect to Coöperative AAC LS U.A., a review of the Company’s registered shareholders as of March 31, 2017.2020. Forbion’s beneficial ownership consists of (i) 987,6734,376,883 Ordinary Shares held by Coöperative AAC LS U.A..ForUniQure B.V., or Coöperative,ForUniQure, (ii) 1,533,6209,859 Ordinary Shares held by Forbion Co-Investment Coöperatief U.A., or FCIManagement, and (iii) 1,865,49411,023 Ordinary Shares and options to purchase 133,757 Ordinary Shares held by Forbion Co-Investment II Coöperatief U.A.,Dr. van Deventer, or FCI II.SvD. Forbion 1 Management B.V., or Forbion 1, the director of Coöperative and FCI,ForUniQure and Forbion 1 Co II Management B.V., the director of FCI II, and Forbion Capital Partners Management Services B.V., or Forbion Capital Partners, may be deemed to have voting and dispositive power over the Ordinary Shares held by Coöperative, FCIForUniQure and FCI II. Investment decisionsForbion Management. Forbion 1, the director of ForUniQure, has voting and investment power over the shares held by ForUniQure, which are exercised through Forbion’s investment committee, consisting of H. A. Slootweg, M. A. van Osch, G. J. Mulder and Dr. van Deventer. None of the members of the investment committee have individual voting and investment power with respect to such shares, and the Ordinary Shares held by Coöperative, FCI and FCI II can be made by any twomembers disclaim beneficial

ownership of such shares except to the duly authorized representativesextent of Coöperative, FCI and FCI II. The addresstheir proportionate pecuniary interests therein. In addition to serving on Forbion’s investment committee, Dr. van Deventer is a partner of Forbion Capital Partners, Coöperative, FCIwhich acts as the investment advisor to the directors of ForUniQure and FCI II is PO Box 5187, 14101 AD Naarden, The Netherlands.

Forbion 1. Dr. van Deventer disclaims beneficial ownership of such Ordinary Shares, except to the extent of his pecuniary interest therein.

(2)              The registered office of FMR, LLC is 245 Summer Street, Boston, Massachusetts 02210, United States. The number of shares reported is based solely on a Schedule 13G/A filed with the Securities and Exchange Commission by FMR, LLC on February 7, 2020.

(3)              The registered office of Federated Hermes Inc. is 1001 Liberty Avenue, Pittsburgh, Pennsylvania 15222-3770, United States. The number of shares reported is based solely on a Schedule 13G/A filed with the Securities and Exchange Commission by Federated Hermes Inc on February 14, 2020.

(4)              The registered office of Redmile Group LLC is One Letterman Drive Building D Suite D3-300, San Francisco, California 94129, United States. The number of shares reported is based solely on a Schedule 13G filed with the Securities and Exchange Commission by FMR, LLC on February 14, 2020.

(5)              The registered office of Nantahala Capital Management, LLC is 130 Main St. 2nd Floor, New Canaan, Connecticut 06840, United States. The number of shares reported is based solely on a Schedule 13G/A filed with the Securities and Exchange Commission by Nantahala Capital Management, LLC on February 14, 2020.

(6)              The registered office of Bristol-Myers Squibb Company is 345 Park Avenue, New York, NYNew York 10154, United States. The number of shares reported is based solely on a Schedule 13G filed with the Securities and Exchange Commission by Bristol-Myers Squibb Company on August 17, 2015.

(3)                     Coller International Partners V-A, L.P.’s beneficial ownership consists of (i) 2,118,520 Ordinary Shares held by Coller International Partners V-A, L.P., or Coller; (ii) 987,673 Ordinary Shares held by Coöperative; (iii) 1,530,501 Ordinary Shares held by FCI; and (iv) 1,865,494 Ordinary Shares held by FCI II. Coller is a limited partner of the Forbion funds. Coller has no dispositive or voting power over Ordinary Shares held by the Forbion funds and disclaims beneficial ownership of such Ordinary Shares except to the extent of its pecuniary interest therein. See footnote 1 above. The general partner of Coller is Coller International General Partner V, L.P. of which Coller Investment Management Limited, or CIM, is the general partner. The directors of CIM are Jeremy Joseph Coller, Cyril Joseph Mahon, Roger Alan Le Tissier, Paul McDonald, Peter Michael Hutton, John Charlton Loveless and Andrew Thane Maden Hitchon and may be deemed to share voting and dispositive power with respect to the ordinary shares held by Coller. The CIM directors disclaim beneficial ownership of such Ordinary Shares except to the extent of their pecuniary interest therein. The address of Coller is c/o Coller Investment Management Limited, PO Box 255, Trafalgar Court, Les Banques, St Peter Port, Guernsey, Channel Islands.

(4)                     The registered office of FMR, LLC is 245 Summer Street, Boston, Massachusetts 02210, United States. The number of shares reported is based solely on a Schedule 13d-1 (b) filed with the Securities and Exchange Commission by FMR, LLC on January 9, 2018.

(5)                     The registered office of Nantahala Capital Management, LLC is 19 Old Kings Highway S, Suite 200, Darien, CT 06820, United States. The number of shares reported is based solely on a Schedule 13G filed with the Securities and Exchange Commission by Nantahala Capital Management, LLC on February 14, 2018.

(6)                     Dr. Petri’s employments ended effective December 31, 2017.

(7)             Includes for theThe persons listed below hold options to purchase the followingnumber of Ordinary Shares subject to options held byshown that person that

are currently exercisable or become exercisable within 60 days of March 31, 2018April 13, 2020, as well as the number of outstanding Ordinary Shares:Shares shown:

Securities Authorized for Issuance under Equity Compensation Plans

The table below provides information about our Ordinary Shares that may be issued under our 2014 Amended and Restated Share Option Plan (the “2014 Restated Plan”),our predecessor plans and outside these plans as of March 31, 2018:April 13, 2020:

(1)              The exercise price for our RSU and PSU awards is $0.00 and is included in the weighted-average exercise price of outstanding options, warrants and rights.

(2)              The exercise price of outstanding options is denominated in euro and translated to $ at the foreign exchange rate as of March 31, 2018.

April 13, 2020.

(3)              TheThese PSU Awards in the foregoing table are measured at target for the outstanding performance-based awards.

(4)              These awards include inducement grants entered into by the Company outside of the 2014 Restated Plan and the predecessor plans.

(5)              At the 2017 annual general meeting of shareholders held on June 14, 2017,2019 Annual General Meeting, our Board was granted the

authority to issue a maximum of 19.9% of the Company’s aggregate issued capital outside of a public offering.  Ordinary Shares may be issued as part of inducement or other option grants but are not restricted to that purposepurpose.

COMPENSATION COMMITTEE REPORT

The Compensation Committee Report is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Securities Exchange Act of 1934, both as amended.

The Compensation Committee hasWe have reviewed and discussed the Management Compensation and Director Compensation disclosuresDiscussion & Analysis contained in this Proxy Statement with the Company’suniQure’s management, and based upon such discussions, the Compensation Committeereview and discussion, we recommended to the Board that the Management Compensation and Director Compensation disclosuresDiscussion & Analysis be included in this Proxy Statement.

The Compensation Committee

MANAGEMENT COMPENSATION DISCUSSION & ANALYSIS

This section discusses the principlesCompensation Discussion and Analysis (the “CD&A”) explains our compensation philosophy, policies underlying our executive compensation programand decisions for our named executive officers.  The Compensation Committee oversees our executive compensation programs and approves or makes recommendations to the Board2019 for approval where appropriate and required by the Compensation Committee’s charter.  In this role, the Compensation Committee reviews and approves all compensation decisions relating to our named executive officers.  For fiscal 2017, the following wereexecutives, whom we refer to in this CD&A and in the following tables as our named executive officers:

(1) Dr. Petry’s employment ended effective December 31, 2017.Executive Summary

ObjectivesOur Business

We are a leader in the field of gene therapy, seeking to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. We are working to advance a focused pipeline of innovative gene therapies that have been developed both internally and through partnerships, such as our collaboration with Bristol Myers-Squibb focused on cardiovascular diseases. We believe our gene therapy technology platform and manufacturing capabilities provide us distinct competitive advantages, including the potential to reduce development risk, cost and time to market. We produce our adeno-associated virus based, or AAV-based, gene therapies in our own facilities with a proprietary, commercial-scale, current good manufacturing practices (“cGMP”) and compliant, manufacturing process. We believe our Lexington, Massachusetts-based facility is one of the world’s leading, most versatile, gene therapy manufacturing facilities.

2019 Performance and Achievements

In 2019 and early 2020, our named executive officers played critical roles in the achievement of our goal to advance and expand our pipeline of leading gene therapy product candidates.

We had significant achievements related to our lead product candidate, etranacogene dezaparvovec or AMT-061.  In January 2019, the first patient was treated in our HOPE-B pivotal study of etranacogene dezaparvovec in hemophilia B, after completing the six-month lead-in phase. In September 2019, we achieved full patient enrollment in the lead-in phase of our HOPE-B study.  Additionally, following the completion of the dosing of a Phase IIb dose-confirmation study of etranacogene dezaparvovec in 2018, we were able to announce updated data on several occasions throughout the year.  The 52-week follow-up data in the Phase IIb study showed that all three patients had stabilized and sustained factor IX activity at therapeutic levels after the one-time administration of etranacogene dezaparvovec.

We also achieved significant milestones in our AMT-130 program for our recombinant AAV5 vector carrying a DNA cassette encoding a microRNA that non-selectively lowers or knocks-down human huntingtin protein in Huntington’s disease patients.   In January 2019, we announced that the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Executive Investigational New Drug (IND) application for AMT-130.  Following that review, our IND became effective, which allowed us to begin our planned Phase I/II study.  In April 2019, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for AMT-130.  Preparations are underway to initiate the world’s first clinical study of a one-time administered therapy for the treatment of Huntington’s disease.